text
stringlengths 0
197k
|
|---|
Participants will be invited to complete a short online survey (this should take around five minutes), advertised to them by the market research panel they have already signed up to. This survey is completely anonymous, and contains some multiple-choice questions, and some that require a short free text response. At the start of the survey one of the four ways to name AMR will be presented to participants in the form of a poster.
|
This study aims to result in an improved understanding regarding the general public's understanding of antibiotic use and investigate the impact of communication on behaviour change. The data from this study may be used to inform future public health campaigns on this topic and improve the use of antibiotics.
|
This study will be conducted online using the Predictiv platform, an online platform built by the Behavioural Insights Team. The study is being run in collaboration between the Behavioural Insights Team and the Institute of Global Health Innovation at Imperial College London.
|
Is it anticipated that the survey will open in April 2024 and be open until recruitment of 4000 participants is complete. This is expected to take 4-6 weeks. conditions: Antimicrobial Resistance conditions: Attitude to Health studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study has been designed as a four-armed online randomised control trial (RCT). This will be conducted using Predictiv, an online platform for running behavioural experiments built by the Behavioural Insights Team The 4,000 participants will be randomised in a 1:1:1:1 ratio to one of four trial arms. primaryPurpose: OTHER masking: SINGLE maskingDescription: Participants will be blinded to the study arm that they have been assigned to. whoMasked: PARTICIPANT count: 4000 type: ESTIMATED name: Presentation of Antimicrobial Resistance measure: Attitudes towards Antimicrobial Resistance (Sentiment) measure: Comprehension measure: Intent measure: Recall measure: Impact on population sub-groups sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06356272 id: 19-006036 id: NCI-2024-00965 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 19-006036 type: OTHER domain: Mayo Clinic Institutional Review Board briefTitle: Oropharynx (OPX) Biomarker Trial overallStatus: RECRUITING date: 2019-11-15 date: 2024-12-15 date: 2025-12-15 date: 2024-04-10 date: 2024-04-10 name: Mayo Clinic class: OTHER briefSummary: The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell carcinoma is absent. conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 conditions: Metastatic Oropharyngeal Squamous Cell Carcinoma conditions: Oropharyngeal Squamous Cell Carcinoma conditions: Recurrent Oropharyngeal Squamous Cell Carcinoma conditions: Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 conditions: Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8 studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 180 type: ESTIMATED name: Non-Interventional Study measure: Change in biomarkers measure: Oncologic outcomes associated with biomarkers measure: Genetic alterations measure: Immunologic biomarkers for predicting progression free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: [email protected] name: Diane Vogen role: CONTACT phone: 507-266-1247 email: [email protected] name: Kathryn M. Van Abel, M.D. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
|
<|newrecord|> nctId: NCT06356259 id: IMMUNRX-01 id: 2023-503917-31 type: EUDRACT_NUMBER briefTitle: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants overallStatus: RECRUITING date: 2023-06-07 date: 2025-01-22 date: 2025-01-22 date: 2024-04-10 date: 2024-04-15 name: ImmunoRx Pharma Inc. class: INDUSTRY briefSummary: The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics with intravenous(IV) administration of IRX-010 in Healthy Participants. conditions: Healthy Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 81 type: ESTIMATED name: IRX-010 name: Placebo measure: Number of participants with Serious Adverse Events measure: Number of participants with Treatment-Emergent Adverse Events measure: Pharmacokinetics(PK): Area under Curve(AUC) measure: Pharmacokinetics(PK): Maximum Concentration (Cmax) measure: Pharmacokinetics(PK): Half-Life (t½) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ICON status: RECRUITING city: Groningen zip: 9728 country: Netherlands name: Renger Tiessen role: CONTACT name: Renger Tiessen role: PRINCIPAL_INVESTIGATOR lat: 53.21917 lon: 6.56667 hasResults: False
|
<|newrecord|> nctId: NCT06356246 id: APHP240363 briefTitle: Oral Health Status of Cystic Fibrosis Patients. An Online Survey in Collaboration With the Vaincre la Mucoviscidose Patient Association. acronym: E-MUCODENT overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-08-01 date: 2024-08-01 date: 2024-04-10 date: 2024-04-10 name: Assistance Publique - Hôpitaux de Paris class: OTHER name: Vaincre la Mucoviscidose briefSummary: Cystic Fibrosis (CF) is a rare hereditary disease with autosomal recessive transmission, affecting 1 in 4700 births in France. Numerous studies have explored the links between oral health and CF, predominantly focusing on a children population. These studies reveal hyposalivation, a risk of dental erosion, an increased prevalence of enamel structural defects, but a reduced prevalence of dental caries in CF children, potentially explained by better oral hygiene. Periodontal disease does not appear to be increased in this population, while the oral quality of life of CF patients has been insufficiently studied.
|
Today, emerging challenges arise due to the increased life expectancy of CF patients, attributed to the rise of modulators such as Kaftrio®, resulting in an adult-majority population in France. The study of periodontal diseases, associated with oral dysbiosis, becomes relevant as they represent bacterial reservoirs that could impact respiratory complications in CF patients.
|
To deepen understanding of the links between oral health and CF, as well as to improve oral health of these patients, it is crucial to update the specific oral profile of this population. A cross-sectional survey using a questionnaire is proposed to include a large number of CF patients in France, aiming for real-life data. This questionnaire is constructed around internationally recognized tools for comparative analysis with normative data. Collaboration with the Patients Association "Vaincre la Mucoviscidose" (VLM) facilitates questionnaire creation, dissemination, and interpretation of results. conditions: Cystic Fibrosis studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 400 type: ESTIMATED measure: Periodontal Risk Screening Score PESS measure: Assess the adherence to good oral hygiene practices and dental follow-up in adult CF patients according to French Union for Oral Health (UFSBD) 2021 measure: Evaluate the risk of dental caries and tooth wear measure: Assess the oral quality of life measure: Evaluate oral dryness sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Marjolaine GOSSET city: Ivry-sur-Seine state: Ile-de-France zip: 94270 country: France name: Marjolaine GOSSET, MD, PhD role: CONTACT phone: +33 (0)1 49 59 48 20 email: [email protected] name: Anne Sophie Duflos, Vaincre La Mucoviscidose role: CONTACT phone: +33 (0)1 40 78 91 97 email: [email protected] lat: 48.81568 lon: 2.38487 hasResults: False
|
<|newrecord|> nctId: NCT06356233 id: FIMBEX briefTitle: Phenotyping and Identification of Biological Markers in STXBP1 Encephalopathy acronym: FIMBEX overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-10-01 date: 2027-12-31 date: 2024-04-10 date: 2024-04-10 name: Fundación Iniciativa para las Neurociencias (FINCE) class: OTHER briefSummary: This is a prospective observational study to evaluate the phenotype of 10 patients under 10 years of age with developmental epileptic encephalopathy due to mutation of the STXBP1 gene. The study will consist of a clinical and neurodevelopmental evaluation, magnetic resonance imaging, prolonged electroencephalogram, cardiological study, and analysis of biomarkers in cerebrospinal fluid. These patients will be followed up for 3 years. The aim of the study is, knowing the baseline phenotype, to analyse the response to commonly used drugs and to anticipate the response to different drugs available on the market in this group of patients based on clinical and biomarker assessment (EEG, MRI and study of specific proteins and neurotransmitters in plasma, urine and CSF). conditions: STXBP1 Encephalopathy With Epilepsy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 10 type: ESTIMATED name: No intervention will be performed measure: CSF biomarkers measure: EEG markers measure: MRI markers measure: Clinical phenotype sex: ALL minimumAge: 1 Month maximumAge: 10 Years stdAges: CHILD facility: Hospital Ruber Internacional city: Madrid zip: 28034 country: Spain name: Alvaro Beltran Corbellini, MD role: CONTACT phone: +34913875250 email: [email protected] name: Antonio Gil-Nagel, MD, PhD role: CONTACT name: Antonio Gil-Nagel, MD role: PRINCIPAL_INVESTIGATOR lat: 40.4165 lon: -3.70256 hasResults: False
|
<|newrecord|> nctId: NCT06356220 id: IRB-P00046867 briefTitle: GF-NOURISH (Gluten Free Nutrition Optimization Through Ultra-processed Food Reduction and Improved Strategies for Health) acronym: GF-NOURISH overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-01 date: 2026-07 date: 2024-04-10 date: 2024-04-10 name: Boston Children's Hospital class: OTHER briefSummary: We propose the Gluten Free Nutrition Optimization through Ultra-processed food Reduction and Improved Strategies for Health (GF-NOURISH) study to demonstrate the feasibility and success of a nutritional education program focused on naturally occurring gluten-free foods and minimizing ultra-processed gluten-free foods. We hypothesize that nutritional educational (GF-NOURISH) intervention will have multiple health benefits conditions: Celiac Disease in Children conditions: Nutrition Disorder, Child studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 1. Study Design: Prospective randomized controlled trial.
|
2. Study population: Children (N=120) with newly diagnosed CeD
|
3. Intervention: Gluten-Free Food Guide, a nutritional education program focused on minimizing ultra-processed foods in gluten-free die(GFFG), OR a conventional GFD nutritional education class. The nutrition educational program will be based on validated GFD education program. We will use a randomized control trial to assess improvement of overall diet quality, changes in body composition, and minimize toxic and nutrient metal exposures associated with processed gluten-free foods. primaryPurpose: PREVENTION masking: NONE count: 120 type: ESTIMATED name: Gluten-Free Diet Education measure: To compare the effect of GFFG versus conventional GFD class on body composition, specifically fat free mass measure: To compare the effect of GFFG vs conventional GFD class on diet quality measure: To compare the effect of GFFG versus conventional GFD on arsenic exposure sex: ALL minimumAge: 2 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Boston Children's Hospital city: Boston state: Massachusetts zip: 02115 country: United States name: Lauren Robertson role: CONTACT name: Nan Du, MD role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 hasResults: False
|
<|newrecord|> nctId: NCT06356207 id: 113-2023 briefTitle: Syncope-Asystole Latency Time in Tilt Table Test: The SALT-TILT Study acronym: SALT-TILT overallStatus: RECRUITING date: 2024-03-20 date: 2026-03 date: 2027-03 date: 2024-04-10 date: 2024-04-11 name: Azienda Ospedaliera di Bolzano class: OTHER briefSummary: Syncope is a common presenting condition. Pacemaker implantation can significantly reduce syncope recurrences in reflex syncope. However, despite careful selection, a substantial proportion of patients treated with pacemakers suffer recurrences of syncope. It is thought that a pronounced vasodepressor component may hinder the efficacy of pacing in patients, preventing adequate cerebral perfusion during the reflex, thus relativizing the anti-bradycardia function of the pacemaker to prevent syncope. It is hypothesised that the time elapsed from the actual loss of consciousness to the asystole recorded on the ECG during Tilt Table Test may be predictive in terms of response to pacemaker therapy, so this parameter becomes the subject of the present study. conditions: Syncope conditions: Pacemaker conditions: Asystole conditions: Neurally Mediated Syncope studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 64 type: ESTIMATED name: Tilt Table Test measure: SALT (Syncope-Asystole Latency Time) measure: Recurrence of syncope measure: Recurrence of syncope sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azienda Sanitaria di Bolzano status: RECRUITING city: Bolzano zip: 39100 country: Italy name: Marco Tomaino, Dr. role: CONTACT lat: 46.49067 lon: 11.33982 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-12-06 uploadDate: 2024-04-04T15:15 filename: Prot_SAP_000.pdf size: 334779 hasResults: False
|
<|newrecord|> nctId: NCT06356194 id: AT-01B-006 briefTitle: Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-05-30 date: 2024-05-30 date: 2024-04-10 date: 2024-04-10 name: Atea Pharmaceuticals, Inc. class: INDUSTRY briefSummary: Drug-drug interaction study of Biktarvy and Bemnifosbuvir/Ruzasvir conditions: Healthy Volunteer Study studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 28 type: ESTIMATED name: Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK name: Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. measure: PK of Biktarvy (BIK: Bictegravir, tenofovir alafenamide, emtricitabine) on the pharmacokinetics (PK) of Bemnifosbuvir (BEM) and Ruzasvir (RZR). measure: To determine the effect of Bemnifosbuvir (BEM)/Ruzasvir (RZR) combination on the PK of Biktarvy (BIK: Bictegravir, tenofovir alafenamide, emtricitabine) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Atea Study Site city: Québec state: Montreal country: Canada name: Atea Study Site role: CONTACT phone: 888-481-1607 email: [email protected] lat: 46.81228 lon: -71.21454 hasResults: False
|
<|newrecord|> nctId: NCT06356181 id: Pro00135143 briefTitle: Training Adaptations With and Without Ventilatory Training Device overallStatus: RECRUITING date: 2024-03-18 date: 2024-09-01 date: 2024-09-01 date: 2024-04-10 date: 2024-04-10 name: University of South Carolina class: OTHER name: MAXIMUS briefSummary: This project aims to assess the effectiveness of using a Respiratory Muscle Training (RMT) device during high-intensity functional training (HIFT) to improve fitness and ventilatory parameters. Primary outcome measures include aerobic, anaerobic, and HIFT measures. Secondary measures include sleep, affect, and mood state questionnaires. Participants will be randomized into one of two groups: with the RMT device and without the RMT device. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 30 type: ESTIMATED name: Respiratory Maximus Training Device name: No Respiratory Training Device measure: Changes in spirometry measure: Changes in aerobic capacity measure: Changes in peak power measure: Changes in ventilatory threshold measure: Changes in countermovement jump measure: Changes in anaerobic capacity measure: Changes in high-intensity functional training test measure: Changes in heart rate at ventilatory threshold measure: Changes in body composition measure: Changes in sleep quality measure: Changes in total mood disturbances measure: Changes in positive mood and emotion measure: Change in blood lactate responses measure: Changes in negative mood and emotion sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: University of South Carolina Sport Science Lab status: RECRUITING city: Columbia state: South Carolina zip: 29208 country: United States name: Shawn M. Arent, PhD role: CONTACT phone: 803-576-8394 email: [email protected] name: Sten O Stray-Gundersen, PhD role: CONTACT email: [email protected] lat: 34.00071 lon: -81.03481 hasResults: False
|
<|newrecord|> nctId: NCT06356168 id: SVR/IVR briefTitle: Virtual Reality in End Stage Kidney Disease overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-12-31 date: 2025-01-31 date: 2024-04-10 date: 2024-04-15 name: University of Pennsylvania class: OTHER briefSummary: The goal of this clinical trial to compare the social virtual reality and individual virtual reality in patients with end stage kidney disease who are hemodialysis. The main aim is to determine if there are differences in symptoms between the groups. Participants will use virtual reality glasses for 30-45 minutes during dialysis sessions for 4 weeks. conditions: End Stage Kidney Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Social Virtual Reality name: Individual Virtual Reality measure: De Jong Gierveld Scale sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06356155 id: UMCC 2023.011 briefTitle: Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer acronym: NEPTUNE overallStatus: NOT_YET_RECRUITING date: 2024-10 date: 2027-07 date: 2027-07 date: 2024-04-10 date: 2024-04-10 name: University of Michigan Rogel Cancer Center class: OTHER briefSummary: This trial is a multi-site, single-arm, phase 2 trial of neoadjuvant combination of enfortumab vedotin and pembrolizumab in cisplatin-eligible patients with high-grade localized/locally advanced cT1-4 N0-1 M0 upper tract urothelial cancer who are deemed eligible for curative-intent surgery (radical nephroureterectomy or distal ureterectomy) followed by adjuvant pembrolizumab. conditions: Urothelial Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: Enfortumab vedotin name: Pembrolizumab measure: Efficacy of the combination of enfortumab vedotin and pembrolizumab as neoadjuvant therapy in cisplatin-eligible patients based off pathological response measure: Assess the safety and toxicity of the combination of enfortumab vedotin and pembrolizumab as neoadjuvant therapy in UTUC measure: Assess whether patients who receive the combination of enfortumab vedotin and pembrolizumab as neoadjuvant therapy have increased surgical complications. measure: Estimate secondary measures of efficacy of neoadjuvant combination enfortumab vedotin and pembrolizumab and pembrolizumab adjuvant therapy (if tolerated) in response evaluable patients with UTUC by measuring RECIST v1.1 measurable disease. measure: Estimate secondary measures of efficacy of neoadjuvant combination enfortumab vedotin and pembrolizumab and pembrolizumab adjuvant therapy (if tolerated) in response evaluable patients with UTUC by measuring 2-year recurrence-free survival (RFS). measure: Estimate secondary measures of efficacy of neoadjuvant combination enfortumab vedotin and pembrolizumab and pembrolizumab adjuvant therapy (if tolerated) in response evaluable patients with UTUC by measuring 2-year overall survival (OS). measure: Estimate the number of patients who are able to complete neoadjuvant combination enfortumab vedotin and pembrolizumab and safely complete definitive surgery. measure: Assess comprehensive profiling of tumor and host characteristics (including genomics and assessment of tumor mutational burden) as predictors of response to treatment. measure: Explore circulating biomarkers as early detectors of cancer recurrence sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Michigan Comprehensive Cancer Center city: Ann Arbor state: Michigan zip: 48109 country: United States name: Irene Tsung, M.D. role: CONTACT phone: 734-936-4385 email: [email protected] name: Irene Tsung, MD role: PRINCIPAL_INVESTIGATOR lat: 42.27756 lon: -83.74088 hasResults: False
|
<|newrecord|> nctId: NCT06356142 id: UMMC-IRB-2023-317 briefTitle: The Effects of Palmar Cooling on Repeated Sprinting Ability overallStatus: NOT_YET_RECRUITING date: 2024-04-04 date: 2025-03-01 date: 2025-03-01 date: 2024-04-10 date: 2024-04-10 name: University of Mississippi Medical Center class: OTHER briefSummary: Repeated sprinting ability is key for athletic performance in a variety of sport settings. Significant degradations in work output (i.e. fatigue) have been shown to develop after just one sprinting bout1. This pilot study aims to investigate the effects that noninvasive transient temperature manipulation has on an individual's ability to perform repeated sprints. The investigators aim to enroll 90 healthy individuals, 18-30 years of age. Participants will be randomized into two groups (Group A, and B). All groups will perform a ten-minute warm-up followed by two minutes of rest. Following the warm-up and rest period, all groups will participate in a series of five sprints, 60 meters in total length with two 180 degree changes in direction. Between sprints, participants will have 10 seconds rest. After the first series of five sprints participants will be given a 2-minute rest interval. Then participants will perform another series of five sprints followed by another 2-minute rest interval. During each rest interval, Group A will utilize a palmar cooling device. Group B will utilize a placebo version of the palmar cooling device. All sprints will be timed. Heart rate recovery will be measured during all rest breaks, and a rating of perceived exertion will be measured at the beginning and end of each resting interval. Delayed onset muscle soreness will be assessed 48 hours post sprinting, utilizing a visual analog scale. conditions: Exercise Induced Fatigue studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 90 type: ESTIMATED name: Palmar Cooling name: Placebo Palmar Cooling measure: Participants Sprinting times measure: Participants Heart Rate Recovery measure: Participants Rating of Perceived exertion measure: Participants Reported Delayed Onset Muscle Soreness sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: University of Mississippi Medical Center city: Jackson state: Mississippi zip: 39216 country: United States name: Jacob Daniels, DPT, EdD role: CONTACT phone: 601-815-4038 email: [email protected] lat: 32.29876 lon: -90.18481 hasResults: False
|
<|newrecord|> nctId: NCT06356129 id: CA073-1020 id: 2023-510178-15 type: REGISTRY domain: EU CT Number id: U1111-1300-8493 type: REGISTRY domain: UTN briefTitle: Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma acronym: GOLSEEK-1 overallStatus: NOT_YET_RECRUITING date: 2024-06-24 date: 2028-08-14 date: 2029-11-20 date: 2024-04-10 date: 2024-04-10 name: Celgene class: INDUSTRY briefSummary: The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL). conditions: Large B-cell Lymphoma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 850 type: ESTIMATED name: Golcadomide name: Placebo name: Rituximab name: Cyclophosphamide name: Doxorubicin name: Vincristine name: Prednisone measure: Progression-free survival (PFS) assessed by the Investigator measure: Overall survival (OS) measure: Event-free survival (EFS) measure: Complete Metabolic Response assessed by the Independent Response Adjudication Committee (IRAC) measure: Minimal residual disease (MRD) negativity rate measure: Progression-free survival (PFS) assessed by the IRAC measure: Objective response (OR) assessed by the Investigator measure: Complete metabolic response (CMR) assessed by the Investigator measure: PFS24 assessed by the Investigator 24 months after randomization measure: Duration of response (DoR) measure: Second progression-free survival (PFS2) assessed by the Investigator measure: Relative dose intensity (%) measure: Time from randomization to meaningful improvement in primary domains of interest in the European Organization for Research and Treatment of Cancer - Quality of Life C30 (EORTC QLQ-C30) Questionnaire measure: Time from randomization to meaningful improvement in primary domains of interest in the Functional Assessment of Cancer Treatment-Lymphoma (FACT-LymS) Questionnaire measure: Mean change from baseline in the EORTC QLQ-C30 measure: Mean change from baseline in the FACT-LymS measure: Number of participants with Adverse Events (AEs) measure: Number of participants with treatment-emergent adverse events (TEAEs) measure: Number of participants with laboratory abnormalities measure: Number of participants with vital sign abnormalities sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Local Institution - 0014 city: Mobile state: Alabama zip: 36604 country: United States name: Site 0014 role: CONTACT lat: 30.69436 lon: -88.04305 facility: Local Institution - 0342 city: San Francisco state: California zip: 94143 country: United States name: Site 0342 role: CONTACT lat: 37.77493 lon: -122.41942 facility: Local Institution - 0287 city: Jacksonville state: Florida zip: 32224 country: United States name: Site 0287 role: CONTACT lat: 30.33218 lon: -81.65565 facility: Local Institution - 0415 city: Margate state: Florida zip: 33063 country: United States name: Site 0415 role: CONTACT lat: 26.24453 lon: -80.20644 facility: Local Institution - 0012 city: Pensacola state: Florida zip: 32504 country: United States name: Site 0012 role: CONTACT lat: 30.42131 lon: -87.21691 facility: Local Institution - 0414 city: Tampa state: Florida zip: 33612 country: United States name: Site 0414 role: CONTACT lat: 27.94752 lon: -82.45843 facility: Local Institution - 0303 city: Atlanta state: Georgia zip: 30322 country: United States name: Site 0303 role: CONTACT lat: 33.749 lon: -84.38798 facility: Local Institution - 0182 city: Chicago state: Illinois zip: 60611 country: United States name: Site 0182 role: CONTACT lat: 41.85003 lon: -87.65005 facility: Local Institution - 0048 city: Skokie state: Illinois zip: 60077 country: United States name: Site 0048 role: CONTACT lat: 42.03336 lon: -87.73339 facility: Local Institution - 0461 city: Des Moines state: Iowa zip: 50309 country: United States name: Site 0461 role: CONTACT lat: 41.60054 lon: -93.60911 facility: Local Institution - 0031 city: Fairway state: Kansas zip: 66205 country: United States name: Site 0031 role: CONTACT lat: 39.02223 lon: -94.6319 facility: Local Institution - 0436 city: Edgewood state: Kentucky zip: 41017 country: United States name: Site 0436 role: CONTACT lat: 39.01867 lon: -84.58189 facility: Local Institution - 0408 city: Baton Rouge state: Louisiana zip: 70809 country: United States name: Site 0408 role: CONTACT lat: 30.45075 lon: -91.15455 facility: Local Institution - 0067 city: Minneapolis state: Minnesota zip: 55407 country: United States name: Site 0067 role: CONTACT lat: 44.97997 lon: -93.26384 facility: Local Institution - 0203 city: Rochester state: Minnesota zip: 55905 country: United States name: Site 0203 role: CONTACT lat: 44.02163 lon: -92.4699 facility: Local Institution - 0437 city: Kansas City state: Missouri zip: 64132 country: United States name: Site 0437 role: CONTACT lat: 39.09973 lon: -94.57857 facility: Local Institution - 0466 city: Reno state: Nevada zip: 89511 country: United States name: Site 0466 role: CONTACT lat: 39.52963 lon: -119.8138 facility: Local Institution - 0049 city: Morristown state: New Jersey zip: 07960 country: United States name: Site 0049 role: CONTACT lat: 40.79677 lon: -74.48154 facility: Local Institution - 0190 city: Buffalo state: New York zip: 14263 country: United States name: Site 0190 role: CONTACT lat: 42.88645 lon: -78.87837 facility: Local Institution - 0369 city: New York state: New York zip: 10028 country: United States name: Site 0369 role: CONTACT lat: 40.71427 lon: -74.00597 facility: Local Institution - 0176 city: New York state: New York zip: 10029 country: United States name: Site 0176 role: CONTACT lat: 40.71427 lon: -74.00597 facility: Local Institution - 0174 city: Chapel Hill state: North Carolina zip: 27599 country: United States name: Site 0174 role: CONTACT lat: 35.9132 lon: -79.05584 facility: Local Institution - 0066 city: Massillon state: Ohio zip: 44646 country: United States name: Site 0066 role: CONTACT lat: 40.79672 lon: -81.52151 facility: Local Institution - 0179 city: Portland state: Oregon zip: 97239 country: United States name: Site 0179 role: CONTACT lat: 45.52345 lon: -122.67621 facility: Local Institution - 0009 city: Pittsburgh state: Pennsylvania zip: 15232 country: United States name: Site 0009 role: CONTACT lat: 40.44062 lon: -79.99589 facility: Local Institution - 0419 city: York state: Pennsylvania zip: 17403 country: United States name: Site 0419 role: CONTACT lat: 39.9626 lon: -76.72774 facility: Local Institution - 0435 city: Fort Sam Houston state: Texas zip: 78234 country: United States name: Site 0435 role: CONTACT lat: 29.45746 lon: -98.4472 facility: Local Institution - 0046 city: Houston state: Texas zip: 77030 country: United States name: Site 0046 role: CONTACT lat: 29.76328 lon: -95.36327 facility: Local Institution - 0424 city: Houston state: Texas zip: 77030 country: United States name: Site 0424 role: CONTACT lat: 29.76328 lon: -95.36327 facility: Local Institution - 0293 city: Richmond state: Virginia zip: 23219 country: United States name: Site 0293 role: CONTACT lat: 37.55376 lon: -77.46026 facility: Local Institution - 0113 city: Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: C1118AAT country: Argentina name: Site 0113 role: CONTACT lat: -34.61315 lon: -58.37723 facility: Local Institution - 0421 city: Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: C1417DTB country: Argentina name: Site 0421 role: CONTACT lat: -34.61315 lon: -58.37723 facility: Local Institution - 0112 city: Buenos Aires zip: 1426 country: Argentina name: Site 0112 role: CONTACT lat: -34.61315 lon: -58.37723 facility: Local Institution - 0136 city: Buenos Aires zip: C1431FWO country: Argentina name: Site 0136 role: CONTACT lat: -34.61315 lon: -58.37723 facility: Local Institution - 0119 city: Ciudad Autónoma de Buenos Aires zip: C1426ANZ country: Argentina name: Site 0119 role: CONTACT lat: -34.61315 lon: -58.37723 facility: Local Institution - 0111 city: Córdoba zip: 5016 country: Argentina name: Site 0111 role: CONTACT lat: -31.4135 lon: -64.18105 facility: Local Institution - 0357 city: Gosford state: New South Wales zip: 2250 country: Australia name: Site 0357 role: CONTACT lat: -33.4244 lon: 151.34399 facility: Local Institution - 0361 city: Sydney state: New South Wales zip: 2560 country: Australia name: Site 0361 role: CONTACT lat: -33.86785 lon: 151.20732 facility: Local Institution - 0358 city: Westmead state: New South Wales zip: 2145 country: Australia name: Site 0358 role: CONTACT lat: -33.80383 lon: 150.98768 facility: Local Institution - 0363 city: Tiwi state: Northern Territory zip: 0810 country: Australia name: Site 0363 role: CONTACT lat: -12.35876 lon: 130.878 facility: Local Institution - 0356 city: Birtinya state: Queensland zip: 4575 country: Australia name: Site 0356 role: CONTACT lat: -26.74322 lon: 153.11913 facility: Local Institution - 0360 city: Southport state: Queensland zip: 4215 country: Australia name: Site 0360 role: CONTACT lat: -27.96724 lon: 153.39796 facility: Local Institution - 0365 city: Frankston state: Victoria zip: 3195 country: Australia name: Site 0365 role: CONTACT lat: -38.14458 lon: 145.12291 facility: Local Institution - 0362 city: Heidelberg state: Victoria zip: 3084 country: Australia name: Site 0362 role: CONTACT lat: -37.75 lon: 145.06667 facility: Local Institution - 0359 city: St Albans state: Victoria zip: 3021 country: Australia name: Site 0359 role: CONTACT lat: -37.73901 lon: 144.80024 facility: Local Institution - 0364 city: Warrnambool state: Victoria zip: 3280 country: Australia name: Site 0364 role: CONTACT lat: -38.38176 lon: 142.48799 facility: Local Institution - 0385 city: Wels state: Oberösterreich zip: 4600 country: Austria name: Site 0385 role: CONTACT lat: 48.16667 lon: 14.03333 facility: Local Institution - 0387 city: Linz zip: 4021 country: Austria name: Site 0387 role: CONTACT lat: 48.30639 lon: 14.28611 facility: Local Institution - 0386 city: Vienna zip: 1140 country: Austria name: Site 0386 role: CONTACT lat: 48.20849 lon: 16.37208 facility: Local Institution - 0255 city: Fortaleza state: Ceará zip: 60115-281 country: Brazil name: Site 0255 role: CONTACT lat: -3.71722 lon: -38.54306 facility: Local Institution - 0297 city: Lago sul state: Distrito Federal zip: 71635580 country: Brazil name: Site 0297 role: CONTACT lat: -15.90603 lon: -47.86366 facility: Local Institution - 0256 city: Goiania state: Goiás zip: 74605-020 country: Brazil name: Site 0256 role: CONTACT lat: -16.67861 lon: -49.25389 facility: Local Institution - 0302 city: Curitiba state: Paraná zip: 81520-060 country: Brazil name: Site 0302 role: CONTACT lat: -25.42778 lon: -49.27306 facility: Local Institution - 0296 city: Niteroi state: Rio De Janeiro zip: 24020-096 country: Brazil name: Site 0296 role: CONTACT lat: -22.88333 lon: -43.10361 facility: Local Institution - 0304 city: Natal state: Rio Grande Do Norte zip: 59075-740 country: Brazil name: Site 0304 role: CONTACT lat: -5.795 lon: -35.20944 facility: Local Institution - 0253 city: Porto Alegre state: Rio Grande Do Sul zip: 90110-270 country: Brazil name: Site 0253 role: CONTACT lat: -30.03306 lon: -51.23 facility: Local Institution - 0246 city: Chapecó state: Santa Catarina zip: 89812-211 country: Brazil name: Site 0246 role: CONTACT lat: -27.09639 lon: -52.61833 facility: Local Institution - 0247 city: Joinville state: Santa Catarina zip: 89201260 country: Brazil name: Site 0247 role: CONTACT lat: -26.30444 lon: -48.84556 facility: Local Institution - 0250 city: Barretos state: São Paulo zip: 14784400 country: Brazil name: Site 0250 role: CONTACT lat: -20.55722 lon: -48.56778 facility: Local Institution - 0249 city: Jaú state: São Paulo zip: 17210-120 country: Brazil name: Site 0249 role: CONTACT lat: -22.29639 lon: -48.55778 facility: Local Institution - 0248 city: Sao Paulo state: São Paulo zip: 01323-903 country: Brazil name: Site 0248 role: CONTACT lat: -23.5475 lon: -46.63611 facility: Local Institution - 0316 city: Sao Paulo state: São Paulo zip: 01509-010 country: Brazil name: Site 0316 role: CONTACT lat: -23.5475 lon: -46.63611 facility: Local Institution - 0252 city: Sao Paulo state: São Paulo zip: 04543-000 country: Brazil name: Site 0252 role: CONTACT lat: -23.5475 lon: -46.63611 facility: Local Institution - 0301 city: São José do Rio Preto state: São Paulo zip: 15090000 country: Brazil name: Site 0301 role: CONTACT lat: -20.81972 lon: -49.37944 facility: Local Institution - 0298 city: Rio de Janeiro zip: 22061-080 country: Brazil name: Site 0298 role: CONTACT lat: -22.90278 lon: -43.2075 facility: Local Institution - 0294 city: São Paulo zip: 01409-902 country: Brazil name: Site 0294 role: CONTACT lat: -23.5475 lon: -46.63611 facility: Local Institution - 0251 city: São Paulo zip: 05652-900 country: Brazil name: Site 0251 role: CONTACT lat: -23.5475 lon: -46.63611 facility: Local Institution - 0394 city: Sofia state: Sofia (stolitsa) zip: 1431 country: Bulgaria name: Site 0394 role: CONTACT lat: 42.69751 lon: 23.32415 facility: Local Institution - 0393 city: Plovdiv zip: 4002 country: Bulgaria name: Site 0393 role: CONTACT lat: 42.15 lon: 24.75 facility: Local Institution - 0392 city: Sofia zip: 1407 country: Bulgaria name: Site 0392 role: CONTACT lat: 42.69751 lon: 23.32415 facility: Local Institution - 0091 city: Victoria state: British Columbia zip: V8R 6V5 country: Canada name: Site 0091 role: CONTACT lat: 48.43294 lon: -123.3693 facility: Local Institution - 0153 city: Montreal state: Quebec zip: H3T 1M5 country: Canada name: Site 0153 role: CONTACT lat: 45.50884 lon: -73.58781 facility: Local Institution - 0073 city: Montreal state: Quebec zip: H4J 1C5 country: Canada name: Site 0073 role: CONTACT lat: 45.50884 lon: -73.58781 facility: Local Institution - 0004 city: Sherbrooke state: Quebec zip: J1H 5N4 country: Canada name: Site 0004 role: CONTACT lat: 45.40008 lon: -71.89908 facility: Local Institution - 0109 city: Chile state: Región Metropolitana De Santiago zip: 8380455 country: Chile name: Site 0109 role: CONTACT facility: Local Institution - 0106 city: Santiago state: Región Metropolitana De Santiago zip: 7500921 country: Chile name: Site 0106 role: CONTACT lat: -33.45694 lon: -70.64827 facility: Local Institution - 0107 city: Santiago state: Región Metropolitana De Santiago zip: 7580206 country: Chile name: Site 0107 role: CONTACT lat: -33.45694 lon: -70.64827 facility: Local Institution - 0110 city: Santiago state: Región Metropolitana De Santiago zip: 8320325 country: Chile name: Site 0110 role: CONTACT lat: -33.45694 lon: -70.64827 facility: Local Institution - 0108 city: Santiago state: Región Metropolitana De Santiago zip: 8330032 country: Chile name: Site 0108 role: CONTACT lat: -33.45694 lon: -70.64827 facility: Local Institution - 0164 city: Viña del Mar state: Valparaíso zip: 0 country: Chile name: Site 0164 role: CONTACT lat: -33.02457 lon: -71.55183 facility: Local Institution - 0195 city: Beijing state: Beijing zip: 100091 country: China name: Site 0195 role: CONTACT lat: 39.9075 lon: 116.39723 facility: Local Institution - 0236 city: Chongqing state: Chongqing zip: 400016 country: China name: Site 0236 role: CONTACT lat: 29.56278 lon: 106.55278 facility: Local Institution - 0196 city: Chongqing state: Chongqing zip: 400030 country: China name: Site 0196 role: CONTACT lat: 29.56278 lon: 106.55278 facility: Local Institution - 0274 city: Fuzhou state: Fujian zip: 350014 country: China name: Site 0274 role: CONTACT lat: 26.06139 lon: 119.30611 facility: Local Institution - 0157 city: Xiamen state: Fujian zip: 361003 country: China name: Site 0157 role: CONTACT lat: 24.47979 lon: 118.08187 facility: Local Institution - 0133 city: Guangzhou state: Guangdong zip: 510515 country: China name: Site 0133 role: CONTACT lat: 23.11667 lon: 113.25 facility: Local Institution - 0240 city: Guangzhou state: Guangdong zip: 510555 country: China name: Site 0240 role: CONTACT lat: 23.11667 lon: 113.25 facility: Local Institution - 0338 city: Nanning state: Guangxi zip: 530021 country: China name: Site 0338 role: CONTACT lat: 22.81667 lon: 108.31667 facility: Local Institution - 0239 city: Harbin state: Heilongjiang zip: 150081 country: China name: Site 0239 role: CONTACT lat: 45.75 lon: 126.65 facility: Local Institution - 0238 city: Zhengzhou state: Henan zip: 450008 country: China name: Site 0238 role: CONTACT lat: 34.75778 lon: 113.64861 facility: Local Institution - 0346 city: Wuhan state: Hubei zip: 430022 country: China name: Site 0346 role: CONTACT lat: 30.58333 lon: 114.26667 facility: Local Institution - 0214 city: Wuhan state: Hubei zip: 430030 country: China name: Site 0214 role: CONTACT lat: 30.58333 lon: 114.26667 facility: Local Institution - 0275 city: Changsha state: Hunan zip: 410013 country: China name: Site 0275 role: CONTACT lat: 28.19874 lon: 112.97087 facility: Local Institution - 0156 city: Suzhou state: Jiangsu zip: 215006 country: China name: Site 0156 role: CONTACT lat: 31.30408 lon: 120.59538 facility: Local Institution - 0237 city: Nanchang state: Jiangxi zip: 330006 country: China name: Site 0237 role: CONTACT lat: 28.68396 lon: 115.85306 facility: Local Institution - 0241 city: Nanchang state: Jiangxi zip: 330029 country: China name: Site 0241 role: CONTACT lat: 28.68396 lon: 115.85306 facility: Local Institution - 0291 city: Changchun state: Jilin zip: 130021 country: China name: Site 0291 role: CONTACT lat: 43.88 lon: 125.32278 facility: Local Institution - 0334 city: Shenyang state: Liaoning zip: 110004 country: China name: Site 0334 role: CONTACT lat: 41.79222 lon: 123.43278 facility: Local Institution - 0169 city: Shenyang state: Liaoning zip: 110015 country: China name: Site 0169 role: CONTACT lat: 41.79222 lon: 123.43278 facility: Local Institution - 0242 city: Jinan state: Shandong zip: 250012 country: China name: Site 0242 role: CONTACT lat: 36.66833 lon: 116.99722 facility: Local Institution - 0344 city: Jinan state: Shandong zip: 250117 country: China name: Site 0344 role: CONTACT lat: 36.66833 lon: 116.99722 facility: Local Institution - 0132 city: Shanghai state: Shanghai zip: 200025 country: China name: Site 0132 role: CONTACT lat: 31.22222 lon: 121.45806 facility: Local Institution - 0339 city: Shanghai state: Shanghai zip: 200032 country: China name: Site 0339 role: CONTACT lat: 31.22222 lon: 121.45806 facility: Local Institution - 0234 city: Taiyuan state: Shanxi zip: 030032 country: China name: Site 0234 role: CONTACT lat: 37.86944 lon: 112.56028 facility: Local Institution - 0141 city: Cheng Du state: Sichuan zip: 610041 country: China name: Site 0141 role: CONTACT facility: Local Institution - 0289 city: Tianjin state: Tianjin zip: 300020 country: China name: Site 0289 role: CONTACT lat: 39.14222 lon: 117.17667 facility: Local Institution - 0155 city: Urumchi state: Xinjiang zip: 830054 country: China name: Site 0155 role: CONTACT facility: Local Institution - 0197 city: Hangzhou state: Zhejiang zip: 310003 country: China name: Site 0197 role: CONTACT lat: 30.29365 lon: 120.16142 facility: Local Institution - 0457 city: Wenzhou state: Zhejiang zip: 325000 country: China name: Site 0457 role: CONTACT lat: 27.99942 lon: 120.66682 facility: Local Institution - 0130 city: Bogota state: Cundinamarca zip: 111151 country: Colombia name: Site 0130 role: CONTACT lat: 4.60971 lon: -74.08175 facility: Local Institution - 0129 city: Bogotá state: Distrito Capital De Bogotá zip: 110131 country: Colombia name: Site 0129 role: CONTACT lat: 4.60971 lon: -74.08175 facility: Local Institution - 0390 city: Zagreb state: Grad Zagreb zip: 10000 country: Croatia name: Site 0390 role: CONTACT lat: 45.81444 lon: 15.97798 facility: Local Institution - 0440 city: Osijek zip: 31000 country: Croatia name: Site 0440 role: CONTACT lat: 45.55111 lon: 18.69389 facility: Local Institution - 0105 city: Brno state: Brno-město zip: 625 00 country: Czechia name: Site 0105 role: CONTACT lat: 49.19522 lon: 16.60796 facility: Local Institution - 0104 city: Hradec Kralove state: Hradec Králové zip: 500 05 country: Czechia name: Site 0104 role: CONTACT lat: 50.20923 lon: 15.83277 facility: Local Institution - 0102 city: Olomouc state: Olomoucký Kraj zip: 779 00 country: Czechia name: Site 0102 role: CONTACT lat: 49.59552 lon: 17.25175 facility: Local Institution - 0120 city: Pilsen state: Plzeňský Kraj zip: 305 99 country: Czechia name: Site 0120 role: CONTACT lat: 49.74747 lon: 13.37759 facility: Local Institution - 0103 city: PRague state: Praha 10 zip: 100 34 country: Czechia name: Site 0103 role: CONTACT lat: 50.08804 lon: 14.42076 facility: Local Institution - 0243 city: Praha 2 zip: 12808 country: Czechia name: Site 0243 role: CONTACT lat: 50.08804 lon: 14.42076 facility: Local Institution - 0285 city: Aarhus state: Midtjylland zip: 8200 country: Denmark name: Site 0285 role: CONTACT lat: 56.15674 lon: 10.21076 facility: Local Institution - 0284 city: Odense state: Syddanmark zip: 5000 country: Denmark name: Site 0284 role: CONTACT lat: 55.39594 lon: 10.38831 facility: Local Institution - 0281 city: Oulu state: Pohjois-Pohjanmaa zip: 90220 country: Finland name: Site 0281 role: CONTACT lat: 65.01236 lon: 25.46816 facility: Local Institution - 0283 city: Kuopio state: Pohjois-Savo zip: 70210 country: Finland name: Site 0283 role: CONTACT lat: 62.89238 lon: 27.67703 facility: Local Institution - 0282 city: Turku state: Varsinais-Suomi zip: 20521 country: Finland name: Site 0282 role: CONTACT lat: 60.45148 lon: 22.26869 facility: Local Institution - 0280 city: Helsinki zip: 00029 country: Finland name: Site 0280 role: CONTACT lat: 60.16952 lon: 24.93545 facility: Local Institution - 0083 city: Nice state: Alpes-Maritimes zip: 06202 country: France name: Site 0083 role: CONTACT lat: 43.70313 lon: 7.26608 facility: Local Institution - 0084 city: Strasbourg state: Alsace zip: 67033 country: France name: Site 0084 role: CONTACT lat: 48.58392 lon: 7.74553 facility: Local Institution - 0090 city: Bordeaux state: Aquitaine zip: 33076 country: France name: Site 0090 role: CONTACT lat: 44.84044 lon: -0.5805 facility: Local Institution - 0324 city: Pessac state: Aquitaine zip: 33600 country: France name: Site 0324 role: CONTACT lat: 44.81011 lon: -0.64129 facility: Local Institution - 0087 city: Marseille state: Bouches-du-Rhône zip: 13273 country: France name: Site 0087 role: CONTACT lat: 43.29551 lon: 5.38958 facility: Local Institution - 0292 city: Dijon state: Côte-d'Or zip: 21000 country: France name: Site 0292 role: CONTACT lat: 47.31667 lon: 5.01667 facility: Local Institution - 0332 city: Brest state: Finistère zip: 29609 country: France name: Site 0332 role: CONTACT lat: 48.3903 lon: -4.48628 facility: Local Institution - 0335 city: Saint-Cloud state: Hauts-de-Seine zip: 92210 country: France name: Site 0335 role: CONTACT lat: 48.84598 lon: 2.20289 facility: Local Institution - 0079 city: Tours state: Indre-et-Loire zip: 37032 country: France name: Site 0079 role: CONTACT lat: 47.38333 lon: 0.68333 facility: Local Institution - 0321 city: Saint Priest en Jarez state: Loire zip: 42271 country: France name: Site 0321 role: CONTACT lat: 45.47501 lon: 4.37614 facility: Local Institution - 0081 city: Lille state: Nord zip: 59000 country: France name: Site 0081 role: CONTACT lat: 50.63297 lon: 3.05858 facility: Local Institution - 0325 city: Nantes state: Pays-de-la-Loire zip: 44000 country: France name: Site 0325 role: CONTACT lat: 47.21725 lon: -1.55336 facility: Local Institution - 0089 city: Pierre-Bénite state: Rhône zip: 69310 country: France name: Site 0089 role: CONTACT lat: 45.7009 lon: 4.82511 facility: Local Institution - 0200 city: Creteil state: Val-de-Marne zip: 94010 country: France name: Site 0200 role: CONTACT lat: 48.78333 lon: 2.46667 facility: Local Institution - 0076 city: Villejuif state: Val-de-Marne zip: 94805 country: France name: Site 0076 role: CONTACT lat: 48.7939 lon: 2.35992 facility: Local Institution - 0306 city: Poitiers state: Vienne zip: 86021 country: France name: Site 0306 role: CONTACT lat: 46.58333 lon: 0.33333 facility: Local Institution - 0244 city: Bayonne zip: 64109 country: France name: Site 0244 role: CONTACT lat: 43.48333 lon: -1.48333 facility: Local Institution - 0315 city: Caen zip: 14033 country: France name: Site 0315 role: CONTACT lat: 49.18585 lon: -0.35912 facility: Local Institution - 0202 city: Lille zip: 59020 country: France name: Site 0202 role: CONTACT lat: 50.63297 lon: 3.05858 facility: Local Institution - 0077 city: Paris zip: 75010 country: France name: Site 0077 role: CONTACT lat: 48.85341 lon: 2.3488 facility: Local Institution - 0323 city: Saint-Pierre zip: 97448 country: France name: Site 0323 role: CONTACT facility: Local Institution - 0383 city: Augsburg state: Bayern zip: 86156 country: Germany name: Site 0383 role: CONTACT lat: 48.37154 lon: 10.89851 facility: Local Institution - 0384 city: Koblenz state: Rheinland-Pfalz zip: 56068 country: Germany name: Site 0384 role: CONTACT lat: 50.35357 lon: 7.57883 facility: Local Institution - 0370 city: Essen zip: 45122 country: Germany name: Site 0370 role: CONTACT lat: 51.45657 lon: 7.01228 facility: Local Institution - 0399 city: Athens state: Attikí zip: 106 76 country: Greece name: Site 0399 role: CONTACT lat: 37.97945 lon: 23.71622 facility: Local Institution - 0396 city: Athens state: Attikí zip: 11527 country: Greece name: Site 0396 role: CONTACT lat: 37.97945 lon: 23.71622 facility: Local Institution - 0397 city: Chaidari state: Attikí zip: 12462 country: Greece name: Site 0397 role: CONTACT lat: 38.01135 lon: 23.66597 facility: Local Institution - 0398 city: Alexandroupolis zip: 08100 country: Greece name: Site 0398 role: CONTACT lat: 40.84995 lon: 25.87644 facility: Local Institution - 0395 city: Ioannina state: Ípeiros zip: 455 00 country: Greece name: Site 0395 role: CONTACT lat: 39.66486 lon: 20.85189 facility: Local Institution - 0160 city: Budapest state: Pest zip: 1122 country: Hungary name: Site 0160 role: CONTACT lat: 47.49801 lon: 19.03991 facility: Local Institution - 0162 city: Kaposvár state: Somogy zip: 7400 country: Hungary name: Site 0162 role: CONTACT lat: 46.36667 lon: 17.8 facility: Local Institution - 0353 city: Nyiregyhaza state: Szabolcs-Szatmár-Bereg zip: 4400 country: Hungary name: Site 0353 role: CONTACT lat: 47.95539 lon: 21.71671 facility: Local Institution - 0161 city: Szombathely state: Vas zip: 9700 country: Hungary name: Site 0161 role: CONTACT lat: 47.23088 lon: 16.62155 facility: Local Institution - 0163 city: Budapest zip: 1088 country: Hungary name: Site 0163 role: CONTACT lat: 47.49801 lon: 19.03991 facility: Local Institution - 0266 city: Debrecen zip: 4032 country: Hungary name: Site 0266 role: CONTACT lat: 47.53333 lon: 21.63333 facility: Local Institution - 0276 city: Anjo state: Aichi zip: 446-8602 country: Japan name: Site 0276 role: CONTACT lat: 34.95828 lon: 137.08054 facility: Local Institution - 0371 city: Nagoya state: Aichi zip: 466-8560 country: Japan name: Site 0371 role: CONTACT lat: 35.18147 lon: 136.90641 facility: Local Institution - 0168 city: Kashiwa state: Chiba zip: 277-8577 country: Japan name: Site 0168 role: CONTACT lat: 35.86224 lon: 139.97732 facility: Local Institution - 0271 city: Ogaki state: Gifu zip: 503-0864 country: Japan name: Site 0271 role: CONTACT lat: 35.35 lon: 136.61667 facility: Local Institution - 0368 city: Sapporo state: Hokkaido zip: 0608648 country: Japan name: Site 0368 role: CONTACT lat: 43.06667 lon: 141.35 facility: Local Institution - 0327 city: Sapporo state: Hokkaido zip: 064-0804 country: Japan name: Site 0327 role: CONTACT lat: 43.06667 lon: 141.35 facility: Local Institution - 0273 city: Amagasaki state: Hyogo zip: 660-8550 country: Japan name: Site 0273 role: CONTACT lat: 34.71667 lon: 135.41667 facility: Local Institution - 0328 city: Himeji state: Hyogo zip: 670-8540 country: Japan name: Site 0328 role: CONTACT lat: 34.81667 lon: 134.7 facility: Local Institution - 0270 city: Kanazawa state: Ishikawa zip: 920-8530 country: Japan name: Site 0270 role: CONTACT lat: 36.6 lon: 136.61667 facility: Local Institution - 0343 city: Morioka state: Iwate zip: 020-0066 country: Japan name: Site 0343 role: CONTACT lat: 39.7 lon: 141.15 facility: Local Institution - 0170 city: Isehara state: Kanagawa zip: 259-1193 country: Japan name: Site 0170 role: CONTACT lat: 35.39932 lon: 139.31019 facility: Local Institution - 0333 city: Yokohama state: Kanagawa zip: 221-0855 country: Japan name: Site 0333 role: CONTACT lat: 35.43333 lon: 139.65 facility: Local Institution - 0320 city: Sendai-shi state: Miyagi zip: 980-8574 country: Japan name: Site 0320 role: CONTACT lat: 38.26667 lon: 140.86667 facility: Local Institution - 0166 city: Osaka-sayama state: Osaka zip: 589-8511 country: Japan name: Site 0166 role: CONTACT lat: 34.69374 lon: 135.50218 facility: Local Institution - 0269 city: Hidaka state: Saitama zip: 350-1298 country: Japan name: Site 0269 role: CONTACT facility: Local Institution - 0288 city: Nagaizumi-cho,Sunto-gun state: Shizuoka zip: 411-8777 country: Japan name: Site 0288 role: CONTACT facility: Local Institution - 0350 city: Bunkyo-ku state: Tokyo zip: 113-8431 country: Japan name: Site 0350 role: CONTACT lat: 35.37517 lon: 139.92991 facility: Local Institution - 0268 city: Itabashiku state: Tokyo zip: 173-8610 country: Japan name: Site 0268 role: CONTACT facility: Local Institution - 0331 city: Chuo state: Yamanashi zip: 409-3898 country: Japan name: Site 0331 role: CONTACT lat: 35.57779 lon: 139.71685 facility: Local Institution - 0348 city: Fukuoka zip: 810-8563 country: Japan name: Site 0348 role: CONTACT lat: 33.6 lon: 130.41667 facility: Local Institution - 0319 city: Fukuoka zip: 811-1395 country: Japan name: Site 0319 role: CONTACT lat: 33.6 lon: 130.41667 facility: Local Institution - 0313 city: Fukuoka zip: 812-8582 country: Japan name: Site 0313 role: CONTACT lat: 33.6 lon: 130.41667 facility: Local Institution - 0272 city: Hiroshima zip: 734-8551 country: Japan name: Site 0272 role: CONTACT lat: 34.4 lon: 132.45 facility: Local Institution - 0171 city: Kumamoto zip: 860-0008 country: Japan name: Site 0171 role: CONTACT lat: 32.80589 lon: 130.69182 facility: Local Institution - 0215 city: Kyoto zip: 602-8566 country: Japan name: Site 0215 role: CONTACT lat: 35.02107 lon: 135.75385 facility: Local Institution - 0329 city: Okayama zip: 700-8558 country: Japan name: Site 0329 role: CONTACT lat: 34.65 lon: 133.93333 facility: Local Institution - 0322 city: Osaka zip: 543-8555 country: Japan name: Site 0322 role: CONTACT lat: 34.69374 lon: 135.50218 facility: Local Institution - 0347 city: Osaka zip: 545-8586 country: Japan name: Site 0347 role: CONTACT lat: 34.69374 lon: 135.50218 facility: Local Institution - 0167 city: Yamagata zip: 990-9585 country: Japan name: Site 0167 role: CONTACT lat: 38.23333 lon: 140.36667 facility: Local Institution - 0149 city: Goyang-si state: Kyǒnggi-do zip: 10408 country: Korea, Republic of name: Site 0149 role: CONTACT lat: 37.65639 lon: 126.835 facility: Local Institution - 0117 city: Seongnam state: Kyǒnggi-do zip: 13620 country: Korea, Republic of name: Site 0117 role: CONTACT lat: 37.43861 lon: 127.13778 facility: Local Institution - 0233 city: Suwon-si state: Kyǒnggi-do zip: 16499 country: Korea, Republic of name: Site 0233 role: CONTACT lat: 37.29111 lon: 127.00889 facility: Local Institution - 0115 city: Busan state: Pusan-Kwangyǒkshi zip: 49201 country: Korea, Republic of name: Site 0115 role: CONTACT lat: 35.10278 lon: 129.04028 facility: Local Institution - 0114 city: Busan state: Pusan-Kwangyǒkshi zip: 49241 country: Korea, Republic of name: Site 0114 role: CONTACT lat: 35.10278 lon: 129.04028 facility: Local Institution - 0131 city: Busan state: Pusan-Kwangyǒkshi zip: 49267 country: Korea, Republic of name: Site 0131 role: CONTACT lat: 35.10278 lon: 129.04028 facility: Local Institution - 0143 city: Seoul state: Seoul-teukbyeolsi [Seoul] zip: 02841 country: Korea, Republic of name: Site 0143 role: CONTACT lat: 37.566 lon: 126.9784 facility: Local Institution - 0069 city: Seoul state: Seoul-teukbyeolsi [Seoul] zip: 03080 country: Korea, Republic of name: Site 0069 role: CONTACT lat: 37.566 lon: 126.9784 facility: Local Institution - 0100 city: Seoul state: Seoul-teukbyeolsi [Seoul] zip: 05505 country: Korea, Republic of name: Site 0100 role: CONTACT lat: 37.566 lon: 126.9784 facility: Local Institution - 0068 city: Seoul state: Seoul-teukbyeolsi [Seoul] zip: 06351 country: Korea, Republic of name: Site 0068 role: CONTACT lat: 37.566 lon: 126.9784 facility: Local Institution - 0070 city: Seoul state: Seoul-teukbyeolsi [Seoul] zip: 06591 country: Korea, Republic of name: Site 0070 role: CONTACT lat: 37.566 lon: 126.9784 facility: Local Institution - 0118 city: Seoul state: Seoul-teukbyeolsi [Seoul] zip: 07345 country: Korea, Republic of name: Site 0118 role: CONTACT lat: 37.566 lon: 126.9784 facility: Local Institution - 0442 city: Daegu state: Taegu-Kwangyǒkshi zip: 41404 country: Korea, Republic of lat: 35.87028 lon: 128.59111 facility: Local Institution - 0116 city: Deagu state: Taegu-Kwangyǒkshi zip: 41404 country: Korea, Republic of facility: Local Institution - 0455 city: Seongnam zip: 463-707 country: Korea, Republic of lat: 37.43861 lon: 127.13778 facility: Local Institution - 0432 city: George Town state: Pulau Pinang zip: 10990 country: Malaysia name: Site 0432 role: CONTACT lat: 5.41123 lon: 100.33543 facility: Local Institution - 0431 city: Kuching state: Sarawak zip: 93586 country: Malaysia name: Site 0431 role: CONTACT lat: 1.54999 lon: 110.33333 facility: Local Institution - 0126 city: Cdmx state: Distrito Federal zip: 14080 country: Mexico name: Site 0126 role: CONTACT facility: Local Institution - 0122 city: Ciudad de México state: Distrito Federal zip: 03100 country: Mexico name: Site 0122 role: CONTACT lat: 19.42847 lon: -99.12766 facility: Local Institution - 0121 city: Mexico City state: Distrito Federal zip: 14080 country: Mexico name: Site 0121 role: CONTACT lat: 19.42847 lon: -99.12766 facility: Local Institution - 0128 city: México state: Distrito Federal zip: 06720 country: Mexico name: Site 0128 role: CONTACT lat: 19.42847 lon: -99.12766 facility: Local Institution - 0127 city: Morelia state: Michoacán zip: 58260 country: Mexico name: Site 0127 role: CONTACT lat: 19.70078 lon: -101.18443 facility: Local Institution - 0139 city: Monterrey state: Nuevo León zip: 66460 country: Mexico name: Site 0139 role: CONTACT lat: 25.67507 lon: -100.31847 facility: Local Institution - 0125 city: Oaxaca de Juarez state: Oaxaca zip: 68020 country: Mexico name: Site 0125 role: CONTACT lat: 17.06542 lon: -96.72365 facility: Local Institution - 0444 city: Hermosillo state: Sonora zip: 83106 country: Mexico name: Site 0444 role: CONTACT lat: 29.1026 lon: -110.97732 facility: Local Institution - 0463 city: Hermosillo state: Sonora zip: 83106 country: Mexico lat: 29.1026 lon: -110.97732 facility: Local Institution - 0123 city: Huixquilucan zip: 52787 country: Mexico name: Site 0123 role: CONTACT lat: 19.35985 lon: -99.35016 facility: Local Institution - 0124 city: Puebla zip: 72424 country: Mexico name: Site 0124 role: CONTACT lat: 19.03793 lon: -98.20346 facility: Local Institution - 0367 city: Dunedin state: Otago zip: 9016 country: New Zealand name: Site 0367 role: CONTACT lat: -45.87416 lon: 170.50361 facility: Local Institution - 0366 city: Hamilton state: Waikato zip: 3240 country: New Zealand name: Site 0366 role: CONTACT lat: -37.78333 lon: 175.28333 facility: Local Institution - 0391 city: Oslo zip: 0310 country: Norway name: Site 0391 role: CONTACT lat: 59.91273 lon: 10.74609 facility: Local Institution - 0336 city: Bydgoszcz state: Kujawsko-pomorskie zip: 85-168 country: Poland name: Site 0336 role: CONTACT lat: 53.1235 lon: 18.00762 facility: Local Institution - 0337 city: Lublin state: Lubelskie zip: 20-090 country: Poland name: Site 0337 role: CONTACT lat: 51.25 lon: 22.56667 facility: Local Institution - 0443 city: Warszawa state: Mazowieckie zip: 02-781 country: Poland name: Site 0443 role: CONTACT lat: 52.22977 lon: 21.01178 facility: Local Institution - 0201 city: Kraków state: Małopolskie zip: 30-727 country: Poland name: Site 0201 role: CONTACT lat: 50.06143 lon: 19.93658 facility: Local Institution - 0388 city: Poznan state: Wielkopolskie zip: 60-175 country: Poland name: Site 0388 role: CONTACT lat: 52.40692 lon: 16.92993 facility: Local Institution - 0330 city: Katowice state: Śląskie zip: 40-027 country: Poland name: Site 0330 role: CONTACT lat: 50.25841 lon: 19.02754 facility: Local Institution - 0286 city: Lisboa zip: 1500-650 country: Portugal name: Site 0286 role: CONTACT lat: 38.71667 lon: -9.13333 facility: Local Institution - 0098 city: Porto zip: 4200-072 country: Portugal name: Site 0098 role: CONTACT lat: 41.14961 lon: -8.61099 facility: Local Institution - 0372 city: San Juan zip: 00909 country: Puerto Rico name: Site 0372 role: CONTACT lat: 18.46633 lon: -66.10572 facility: Local Institution - 0375 city: Bucuresti state: București zip: 022328 country: Romania name: Site 0375 role: CONTACT lat: 44.42802 lon: 26.09665 facility: Local Institution - 0381 city: Bucuresti state: București zip: 022328 country: Romania name: Site 0381 role: CONTACT lat: 44.42802 lon: 26.09665 facility: Local Institution - 0417 city: Tg.Mures state: Mureș zip: 540136 country: Romania name: Site 0417 role: CONTACT facility: Local Institution - 0380 city: Brasov zip: 500052 country: Romania name: Site 0380 role: CONTACT lat: 45.64861 lon: 25.60613 facility: Local Institution - 0374 city: București zip: 022238 country: Romania name: Site 0374 role: CONTACT lat: 44.42802 lon: 26.09665 facility: Local Institution - 0377 city: București zip: 030171 country: Romania name: Site 0377 role: CONTACT lat: 44.42802 lon: 26.09665 facility: Local Institution - 0382 city: București zip: 030171 country: Romania name: Site 0382 role: CONTACT lat: 44.42802 lon: 26.09665 facility: Local Institution - 0378 city: București zip: 050098 country: Romania name: Site 0378 role: CONTACT lat: 44.42802 lon: 26.09665 facility: Local Institution - 0423 city: Cluj zip: 400015 country: Romania name: Site 0423 role: CONTACT lat: 46.76667 lon: 23.6 facility: Local Institution - 0379 city: Iași zip: 700483 country: Romania name: Site 0379 role: CONTACT lat: 47.16667 lon: 27.6 facility: Local Institution - 0376 city: Sibiu zip: 550245 country: Romania name: Site 0376 role: CONTACT lat: 45.8 lon: 24.15 facility: Local Institution - 0439 city: Dammam state: Ash Sharqīyah zip: 31444 country: Saudi Arabia name: Site 0439 role: CONTACT lat: 26.43442 lon: 50.10326 facility: Local Institution - 0416 city: Riyadh zip: 12713 country: Saudi Arabia name: Site 0416 role: CONTACT lat: 24.68773 lon: 46.72185 facility: Local Institution - 0427 city: Singapore state: Central Singapore zip: 169608 country: Singapore name: Site 0427 role: CONTACT lat: 1.28967 lon: 103.85007 facility: Local Institution - 0355 city: Banska Bystrica state: Banskobystrický Kraj zip: 97517 country: Slovakia name: Site 0355 role: CONTACT lat: 48.73946 lon: 19.15349 facility: Local Institution - 0204 city: Bratislava zip: 83101 country: Slovakia name: Site 0204 role: CONTACT lat: 48.14816 lon: 17.10674 facility: Local Institution - 0412 city: A Coruña state: A Coruña [La Coruña] zip: 15006 country: Spain name: Site 0412 role: CONTACT lat: 43.37135 lon: -8.396 facility: Local Institution - 0071 city: L'Hospitalet Del Llobregat state: Barcelona [Barcelona] zip: 08908 country: Spain name: Site 0071 role: CONTACT facility: Local Institution - 0389 city: Barakaldo state: Bizkaia zip: 48903 country: Spain name: Site 0389 role: CONTACT lat: 43.29639 lon: -2.98813 facility: Local Institution - 0172 city: Santa Cruz de Tenerife state: Canarias zip: 38010 country: Spain name: Site 0172 role: CONTACT lat: 28.46824 lon: -16.25462 facility: Local Institution - 0314 city: San Sebastian state: Gipuzkoa zip: 20014 country: Spain name: Site 0314 role: CONTACT lat: 43.31283 lon: -1.97499 facility: Local Institution - 0096 city: Majadahonda state: Madrid, Comunidad De zip: 28222 country: Spain name: Site 0096 role: CONTACT lat: 40.47353 lon: -3.87182 facility: Local Institution - 0409 city: El Palmar, Murcia state: Murcia, Región De zip: 30120 country: Spain name: Site 0409 role: CONTACT facility: Local Institution - 0092 city: Malaga state: Málaga zip: 29010 country: Spain name: Site 0092 role: CONTACT lat: 36.72016 lon: -4.42034 facility: Local Institution - 0095 city: Cáceres zip: 10003 country: Spain name: Site 0095 role: CONTACT lat: 39.47649 lon: -6.37224 facility: Local Institution - 0072 city: Madrid zip: 28006 country: Spain name: Site 0072 role: CONTACT lat: 40.4165 lon: -3.70256 facility: Local Institution - 0093 city: Salamanca zip: 37007 country: Spain name: Site 0093 role: CONTACT lat: 40.96882 lon: -5.66388 facility: Local Institution - 0277 city: Uppsala state: Uppsala Län [se-03] zip: 751 85 country: Sweden name: Site 0277 role: CONTACT lat: 59.85882 lon: 17.63889 facility: Local Institution - 0278 city: Linköping state: Östergötlands Län [se-05] zip: 581 85 country: Sweden name: Site 0278 role: CONTACT lat: 58.41086 lon: 15.62157 facility: Local Institution - 0142 city: Chiayi City state: Chiayi zip: 613 country: Taiwan name: Site 0142 role: CONTACT lat: 23.47917 lon: 120.44889 facility: Local Institution - 0146 city: Tainan City state: Tainan zip: 71004 country: Taiwan name: Site 0146 role: CONTACT lat: 22.99083 lon: 120.21333 facility: Local Institution - 0159 city: Kaohsiung zip: 83301 country: Taiwan name: Site 0159 role: CONTACT lat: 22.61626 lon: 120.31333 facility: Local Institution - 0135 city: Taichung zip: 40447 country: Taiwan name: Site 0135 role: CONTACT lat: 24.1469 lon: 120.6839 facility: Local Institution - 0145 city: Taichung zip: 407 country: Taiwan name: Site 0145 role: CONTACT lat: 24.1469 lon: 120.6839 facility: Local Institution - 0134 city: Taipei zip: 10002 country: Taiwan name: Site 0134 role: CONTACT lat: 25.04776 lon: 121.53185 facility: Local Institution - 0147 city: Taipei zip: 112 country: Taiwan name: Site 0147 role: CONTACT lat: 25.04776 lon: 121.53185 facility: Local Institution - 0158 city: Taoyuan zip: 333 country: Taiwan name: Site 0158 role: CONTACT lat: 24.95233 lon: 121.20193 facility: Local Institution - 0434 city: Bangkok state: Krung Thep Maha Nakhon zip: 10330 country: Thailand name: Site 0434 role: CONTACT lat: 13.75398 lon: 100.50144 facility: Local Institution - 0426 city: Bangkok state: Krung Thep Maha Nakhon zip: 10700 country: Thailand name: Site 0426 role: CONTACT lat: 13.75398 lon: 100.50144 facility: Local Institution - 0428 city: Chiang Mai zip: 50200 country: Thailand name: Site 0428 role: CONTACT lat: 18.79038 lon: 98.98468 facility: Local Institution - 0400 city: Ankara zip: 06100 country: Turkey name: Site 0400 role: CONTACT lat: 39.91987 lon: 32.85427 facility: Local Institution - 0405 city: Ankara zip: 06100 country: Turkey name: Site 0405 role: CONTACT lat: 39.91987 lon: 32.85427 facility: Local Institution - 0422 city: Ankara zip: 06170 country: Turkey name: Site 0422 role: CONTACT lat: 39.91987 lon: 32.85427 facility: Local Institution - 0401 city: Ankara zip: 06200 country: Turkey name: Site 0401 role: CONTACT lat: 39.91987 lon: 32.85427 facility: Local Institution - 0406 city: İzmir zip: 35100 country: Turkey name: Site 0406 role: CONTACT lat: 38.41273 lon: 27.13838 facility: Local Institution - 0403 city: Mersin zip: 33343 country: Turkey name: Site 0403 role: CONTACT lat: 36.79526 lon: 34.61792 facility: Local Institution - 0407 city: Samsun zip: 55270 country: Turkey name: Site 0407 role: CONTACT lat: 41.27976 lon: 36.3361 facility: Local Institution - 0402 city: Trabzon zip: 61080 country: Turkey name: Site 0402 role: CONTACT lat: 41.005 lon: 39.72694 hasResults: False
|
<|newrecord|> nctId: NCT06356116 id: CMUH111-REC3-029 briefTitle: Rehabilitation After Direct Anterior Approach for Total Hip Arthroplasty overallStatus: RECRUITING date: 2023-11-14 date: 2024-10-31 date: 2024-12-31 date: 2024-04-10 date: 2024-04-11 name: China Medical University Hospital class: OTHER briefSummary: The causes for total hip arthroplasty (THA) in Taiwan include ischemic necrosis of the femoral head and degenerative osteoarthritis. Contemporary, the surgical approach for total hip replacement mostly adopts the lateral approach. However, the direct anterior approach (DAA) has gained attention gradually due to its characteristics such as muscle preservation, small surgical incision length, and few surgical complications. Nevertheless, literature lacks detailed exploration or long-term follow-up on the recovery of physical functions related to fall occurrence after this type of surgery. It limits the establishment and design of suitable post-operative rehabilitation plans. Therefore, this study aims to explore and follow-up the functional recovery in patients who undergo the DAA for hip replacement using current usual care and new-designed accelerated rehabilitation program. The proposed method involves recruiting 30 patients who will undergo the DAA for total hip replacement, who will receive the current usual care plan; and another 30 patients will receive the accelerated rehabilitation program. The assessments will be conducted before the surgery and at 2, 4, 8, and 12 weeks after the operation, evaluating hip joint function, hip abduction and flexion muscle strength, balance function, and gait performance. The statistical analysis will utilize mixed-model two-factor ANOVA, comparing the preoperative and postoperative recovery of patients undergoing the DAA with different intervention programs and at different time points. The expected outcome of this study is to enhance the understanding of the functional recovery of patients undergoing the DAA for total hip replacement in terms of hip joint function, muscle strength, balance function, and gait performance after surgery. This information will help establish the targeted DAA postoperative treatment plans, which will be practically applied to patients and compared with the current usual care to assess its effectiveness, ultimately contributing to more efficient rehabilitation plans in the future. conditions: Total Hip Arthroplasty studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 60 type: ESTIMATED name: Usual care name: Accelerated rehabilitation measure: Functional recovery questionaire measure: Maximum muscle strength measure: Quality of Life questionaire measure: Balance function measure: Gait performance measure: Walking speed sex: ALL minimumAge: 25 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: China Medical University Hospital status: RECRUITING city: Taichung zip: 404 country: Taiwan name: Hsiu-Chen Lin, PhD role: CONTACT phone: +886-4-22053366 phoneExt: 7303 email: [email protected] lat: 24.1469 lon: 120.6839 hasResults: False
|
<|newrecord|> nctId: NCT06356103 id: 0107060 briefTitle: Efficacy Of High Caloric Whey-Based Partially Hydrolyzed Formula On Undernourished Neurologically Impaired Children overallStatus: COMPLETED date: 2022-06-01 date: 2022-12-31 date: 2023-07-15 date: 2024-04-10 date: 2024-04-10 name: Alexandria University class: OTHER briefSummary: Purpose: Undernutrition is common in neurologically impaired children. It increases the burden of comorbidities and affects the quality of life of these children. It must be recognized and treated as early as possible. This study aimed primarily to compare the efficacy of high-caloric whey-based partially hydrolyzed formula (HC-WPHF) versus standard feeding on the nutritional status reflected by growth parameters and feeding tolerance in undernourished children with neurological impairment (NI). The secondary aim was to compare the change in these parameters after using HC-WPHF for 3 and 6 months. conditions: Nutrition Disorder, Child conditions: Neurologic Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A Randomized Controlled Study primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 100 type: ACTUAL name: High Caloric Whey-Based Partially Hydrolyzed Formula name: nutritional feeding according to ESPGHAN guidelines measure: To compare the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the weight in kilogram in undernourished children with neurological impairment (NI). measure: To compare the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the height/length in centimeter in undernourished children with neurological impairment (NI). measure: To compare the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the body mass index (BMI) in children with neurological impairment (NI). measure: To compare the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the head circumference in centimeter in undernourished children with neurological impairment (NI) measure: To follow up the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the weight in kilogram in undernourished children with neurological impairment (NI) for 3 and 6 months measure: To follow up the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the height/length in Centimeter in undernourished children with neurological impairment (NI) for 3 and 6 months measure: To follow up the efficacy of high-caloric whey-based partially hydrolyzed formula versus on the body mass index in undernourished children with neurological impairment (NI) for 3 and 6 months measure: To follow up the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the head circumference in Centimeter in undernourished children with neurological impairment (NI) for 3 and 6 months sex: ALL minimumAge: 2 Years maximumAge: 6 Years stdAges: CHILD facility: Alexandria University Children Hospital city: Alexandria zip: 23445 country: Egypt lat: 31.21564 lon: 29.95527 hasResults: False
|
<|newrecord|> nctId: NCT06356090 id: 2023.0322 - NL84369.018.23 briefTitle: SPACE: a Parent-based Treatment for Pediatric OCD overallStatus: RECRUITING date: 2023-11-23 date: 2025-03-31 date: 2025-03-31 date: 2024-04-10 date: 2024-04-10 name: Chaim Huijser class: OTHER name: Levvel briefSummary: This study will investigate the parent-based treatment SPACE: Supportive Parenting for Anxious Childhood Emotions. The aim of this study is to investigate whether SPACE is effective in reducing family accommodation (FA) and OCD symptoms in children with a complex obsessive-compulsive disorder (OCD), that did not or cannot benefit from first line treatment. conditions: Obsessive-Compulsive Disorder conditions: Obsessive-Compulsive Disorder in Children conditions: Obsessive-Compulsive Disorder in Adolescence conditions: Anxiety Disorders and Symptoms studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single case experimental design (SCED) with multiple baselines primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Supportive Parenting for Anxious Childhood Emotions (SPACE) measure: (Change in) OCD severity measure: (Change in) family accommodation (parent report) measure: (Change in) Family accommodation (child report) measure: Daily (change in) OCD symptoms measure: Daily (change in) family accommodation measure: Symptoms of child anxiety measure: Symptoms of child depression measure: Symptoms of autism measure: Quality of life (parent-report) measure: Quality of life (child-report) measure: Clinical impression of outcome measure: Treatment progress measure: Session experience measure: Treatment adherence measure: Demographic variables measure: Psychiatric DSM-5 diagnosis of the child measure: Parenting burden measure: Psychopathology and adaptive functioning of parents measure: Child Behavior Checklist (CBCL, parent-report) measure: Youth Self-report (YSR) (child-report) measure: Teacher Report Form Emotional- and behavioral problems of the child (teacher- report) measure: Treatment satisfaction sex: ALL minimumAge: 7 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Amsterdam UMC / Levvel (Academic centre for child & adolescent psychiatry) status: RECRUITING city: Amsterdam country: Netherlands name: J.D.K. Veeger role: CONTACT name: C. Huijser, Dr. role: PRINCIPAL_INVESTIGATOR lat: 52.37403 lon: 4.88969 hasResults: False
|
<|newrecord|> nctId: NCT06356077 id: OBPM_HTN2024 briefTitle: Evaluation of the Satisfaction of a Hypertensive Population in Their Use of the Aktiia 24/7 Blood Pressure Monitor acronym: OBPM_HTN2024 overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2027-12 date: 2027-12 date: 2024-04-10 date: 2024-04-10 name: Aktiia SA class: INDUSTRY briefSummary: OBPM_HTN2024 study was designed by AKTIIA SA to evaluate how a hypertensive population, reflective of the United States and encompassing a range of phenotypes, perceives the Aktiia 24/7 device (Aktiia G1) during their first 3 months of use. conditions: Hypertension studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 5000 type: ESTIMATED measure: Preferences of subjects regarding the method to monitor their blood pressure between Aktiia Bracelet, Home Blood Pressure Monitor, or Ambulatory Blood Pressure Monitor measure: Frequency of Aktiia app use measure: Frequency of use of Aktiia device as compared to previously use other blood pressure monitors measure: Evaluation of subject's experience in using the Aktiia App measure: Evaluation of the most valuable data on the Aktiia Mobile App by subjects sex: ALL minimumAge: 21 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06356064 id: E2-23-3834 briefTitle: Radial or Focus Extracorporeal Shock Wave Therapy in Epin Calcanei overallStatus: COMPLETED date: 2023-05-15 date: 2023-12-15 date: 2024-01-15 date: 2024-04-10 date: 2024-04-22 name: Ankara City Hospital Bilkent class: OTHER briefSummary: Objective: The aim of the study was to investigate the effectiveness of radial and focused ESWT treatment on pain, function, and size of the calcaneal spur in patients with a clinical and radiological diagnosis of epin calcanei.
|
Methods: A total of 112 patients aged between 18 and 95 years were randomly divided into two groups: group 1 received rESWT (2.4 bar 12 hz 2000 beats), and group 2 received fESWT (0.14 bar 14 hz 1000 beats) three times a week for three weeks. All patients were evaluated using the Visual Analog Scale (VAS)-pain and Foot Function Index (FFI) before and after the treatment, at 4 weeks and 12 weeks. Epin size was measured radiographically in the patients before and after the treatment at the 12-week follow-up. conditions: Spur, Heel studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 112 type: ACTUAL name: Extracorporeal shock wave therapy measure: Visual Analog Scale measure: Functional Foot Index measure: Radiographic assesment, epin size sex: ALL minimumAge: 18 Years maximumAge: 95 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Özge TEZEN city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
|
<|newrecord|> nctId: NCT06356051 id: Gbuyukyilmaz briefTitle: Cardiovascular Disease Risk in Children With Type 1 Diabetes Mellitus overallStatus: COMPLETED date: 2023-01-01 date: 2023-06-01 date: 2023-09-01 date: 2024-04-10 date: 2024-04-10 name: Ankara City Hospital Bilkent class: OTHER briefSummary: Epicardial fat thickness, carotid intima-media thickness, and augmentation index from arterial stiffness indicators are increased in children with T1DM compared to the healthy control group. These results support the idea that children with T1DM present significant changes in important subclinical indicators for the development of cardiovascular disease. conditions: Type 1 Diabetes studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 202 type: ACTUAL name: Echocardiography measure: Epicardial fat thickness measure: carotid intima-media thickness measure: arterial stiffness parameters such as pulse wave velocity, augmentation index sex: ALL minimumAge: 8 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Ankara Bilkent City Hospital city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-01-04 uploadDate: 2024-03-30T05:04 filename: Prot_SAP_000.pdf size: 347934 hasResults: False
|
<|newrecord|> nctId: NCT06356038 id: Prot. n. 76 SA/2022 briefTitle: Phrenic Nerve Infiltration: Pulmonary Expansion and Pain Control overallStatus: ACTIVE_NOT_RECRUITING date: 2022-03-09 date: 2025-01-02 date: 2025-01-02 date: 2024-04-10 date: 2024-04-10 name: Azienda Ospedaliera "Sant'Andrea" class: OTHER briefSummary: Between January 2021-2023, 65 consecutive patients at risk for PAL (defined in accordance to "2019 Society of Thoracic Surgery score-criteria of PAL") underwent lung resection (lobectomy or sublobar resection) for malignancy. 5 patients were lost. The remaining have been assigned with a 1:2 randomization into: group A (22 patients), received intra-operative phrenic nerve infiltration with Ropivacaine 10 mg/ml in the peri-neurotic fat on the pericardium and group B (38 patients), did not receive infiltration. Data on hemidiaphragm elevation, air leaks, pain at 24 and 72 hours post-surgery, shoulder pain, length of hospital stay, length of chest tube permanence, were retrospectively collected and compared.The aim of the study is to investigate the effect of intra-operative phrenic nerve infiltration with long acting anesthetic in patients at high risk for PAL, improving pulmonary expansion after surgery, and reducing air leaks, while controlling post-operative pain. conditions: Prolonged Air Leak conditions: Post-operative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 66 type: ACTUAL name: intra-operative phrenic nerve infiltration measure: rate of pulmonary expansion due by phrenic nerve intra-operative local anaesthetic infiltration measure: rate of post-operative pain control after intra-operative phrenic nerve infiltration with local anaesthetic sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azienda Ospedaliera "Sant'Andrea" city: Roma country: Italy lat: 41.89193 lon: 12.51133 hasResults: False
|
<|newrecord|> nctId: NCT06356025 id: 52082 id: 2024-512546-42 type: EUDRACT_NUMBER briefTitle: Botulinum Toxin Injection in the UES for R-CPD acronym: BOTUS R-CPD overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2027-07 date: 2027-07 date: 2024-04-10 date: 2024-04-10 name: AZ Delta class: OTHER name: KU Leuven briefSummary: The aim of this study is to assess the effect of botulinum toxin injection into the upper esophageal sphincter in a double blind, placebo controlled study. Investigators want to assess the effect on symptoms short term (1-20 weeks after BT injection), and long term (48 weeks after BT injection).
|
This is a prospective double-blind randomized placebo-controlled study. Questionnaires assessing symptoms will be filled out on several occasions. At 20 weeks, a reassessment of symptoms will be done, without unblinding patients or investigator. Failures (to BT or placebo, defined as no clinical improvement or improvement less than 50%) will get the chance to receive a second procedure with active treatment (BT) in open label. conditions: Retrograde Cricopharyngeus Dysfunction studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: botulinum toxin type A name: Sodium Chloride 0.9% Inj measure: Change of at least 50% of 'inability to belch' using the symptom questionnaire at week 12. measure: Change in associated gastrointestinal symptoms: abdominal bloating/discomfort measure: Change in associated gastrointestinal symptoms: abdominal/chest pain measure: Change in associated gastrointestinal symptoms: flatulence measure: Change in associated gastrointestinal symptoms: gurgling noises from the chest/lower neck measure: Change of at least 50% of 'inability to belch' during long term follow-up at week 20, and at 48 weeks. measure: Overall treatment effect (OTE) measure: Overall symptom severity (OSS) measure: EuroQol-5D (EQ-5D) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06356012 id: 71163523.1.0000.5437 briefTitle: Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated With Imiquimod overallStatus: NOT_YET_RECRUITING date: 2024-04-02 date: 2026-12-31 date: 2028-12-31 date: 2024-04-10 date: 2024-04-10 name: Barretos Cancer Hospital class: OTHER name: Fundação de Amparo à Pesquisa do Estado de São Paulo name: Farmoquimica S.A. name: Hospital de Cancer de Barretos - Fundacao Pio XII briefSummary: The goal of this clinical trial is to identify the immunophenotypic profile of the local immune response, the cervicovaginal microenvironment and the microbiological profile of women with CIN 3 treated with imiquimod. Participants will be divided in 3 groups: CIN 3 who will use 16 doses of imiquimod in the uterine cervix, applied twice a week and will be treated with LEEP procedure; 2) patients with CIN 3 who will undergo standard treatment with LEEP procedure; 3) patients with negative cytology and HPV (human papillomavirus) test. Blood and cervicovaginal lavage collections will be performed at different times, for comparisons between cellular response profiles to imiquimod during treatment and baseline levels in healthy patients. conditions: HSIL, High-Grade Squamous Intraepithelial Lesions conditions: Vaginal Microbiome conditions: Biomarkers studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 96 type: ESTIMATED name: Imiquimod name: Loop Electrosurgical Excision Procedure measure: Number of participants with histological regression of High-grade squamous intraepithelial lesion (HSIL) measure: Identification of immune response in vaginal and plasma collection measure: Correlation between vaginal microbiome and immunological response sex: FEMALE minimumAge: 25 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06355999 id: 2007p000646-F briefTitle: Levari Exp.20: 2D - Partial Feedback overallStatus: COMPLETED date: 2021-05-01 date: 2021-06-01 date: 2021-06-01 date: 2024-04-10 date: 2024-04-10 name: Brigham and Women's Hospital class: OTHER briefSummary: Suppose that observers are trying to classify a spot on the skin as normal or abnormal and suppose that the two attributes that are important are the color and shape of the spot. The investigators have found that perceptual decisions of this short are shaped by the prevalence of the target abnormality and by the feedback that observers (Os) receive. If abnormal spots are rare (low prevalence), Os will tend to become more conservative about calling spots abnormal. In this experiment, Os see items defined by color and shape. They are looking for one combination (bumpy green). Bumpy green targets can be common (50% prevalence) or rare (10%). Os in one group will get feedback about their responses based on color. The other group will receive feedback based on shape. The investigators will look for effects of prevalence and of the type of feedback. The goal is to better understand perceptual decisions in settings like clinical evaluation of skin lesions. conditions: Form Perception conditions: Color Perception conditions: Decision Making studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Two groups, each receiving different feedback primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: Observers are naive as to the purpose of the experiment until after participation whoMasked: PARTICIPANT count: 55 type: ACTUAL name: Feedback measure: Participant naming of visual stimuli sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Visual Attention Lab / Brigham and Women's Hospital city: Boston state: Massachusetts zip: 02215 country: United States lat: 42.35843 lon: -71.05977 hasResults: False
|
<|newrecord|> nctId: NCT06355986 id: 39039039AFL4016 briefTitle: Computerized Decision Support to Prevent Stroke in Atrial Fibrillation acronym: AF-ALERT3 overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2025-07-30 date: 2026-07-30 date: 2024-04-10 date: 2024-04-10 name: Brigham and Women's Hospital class: OTHER name: Janssen, LP briefSummary: Atrial fibrillation (AF) is the most preventable cause of stroke. However, despite widely available risk stratification tools, numerous options for oral anticoagulation, and evidence-based practice guidelines, anticoagulation for stroke prevention in AF is consistently under-prescribed. In a pair of observational cohort analyses within the Mass General Brigham (MGB) health system, prescription of anticoagulation for stroke prevention in AF was less frequent in ambulatory clinic patients than in those who were hospitalized at the time of assessment (46.9% vs. 57.2%). Two single academic medical center randomized controlled trials demonstrated success for increasing adherence to guideline recommendations for stroke prevention in AF. To address the feasibility and impact of a computerized decision support (CDS) strategy in the non-tertiary care, community medical center setting, this study will involve a multicenter, cluster-randomized controlled trial of a more sophisticated CDS focused not only on implementation stroke prevention but also on bleeding risk assessment and management. conditions: Atrial Fibrillation conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 2500-patient U.S. multicenter, community-based Quality Improvement Initiative in the form of a cluster-randomized controlled trial. primaryPurpose: PREVENTION masking: TRIPLE maskingDescription: Assignment to a particular cluster (ALERT or NO ALERT) will be masked to the patient participant, investigator, and outcomes assessor. Since the intervention is a computer alert to the provider of record, he/she will be aware of whether or not a notification is provided. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 2500 type: ESTIMATED name: Alert-based computerized decision support measure: Frequency of prescription of anticoagulation at 90 days in high-risk AF patients in the outpatient setting who are not being prescribed anticoagulation for stroke prevention at the time of study enrollment measure: Frequency of major bleeding at 6 months from enrollment. measure: Frequency of failure to prescribe anticoagulation because of perceived risk of bleeding in high-risk AF patients in the outpatient setting who are not being prescribed anticoagulation at the time of study enrollment and are assigned to the alert group measure: Frequency of a composite of major adverse cardiovascular events, defined as cerebrovascular accident, systemic embolism, any MI, symptomatic VTE, or all-cause mortality at 6 months from enrollment measure: Frequency of referral for left atrial appendage occlusion among patients with high bleeding risk at 6 months will be reported measure: Frequency of clinically relevant nonmajor bleeding is defined as overt bleeding not meeting the criteria for major bleeding at 6 months. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St. Elizabeth Health city: Edgewood state: Kentucky zip: 41017 country: United States name: Benjamin Peterson, MD role: CONTACT phone: 617-987-1046 email: [email protected] lat: 39.01867 lon: -84.58189 facility: Mass General Brigham city: Boston state: Massachusetts zip: 02115 country: United States name: Gregory Piazza, MD, MS role: CONTACT phone: 781-956-5525 email: [email protected] lat: 42.35843 lon: -71.05977 hasResults: False
|
<|newrecord|> nctId: NCT06355973 id: 2024-01-061 briefTitle: A Pilot Study for Efficacy of Cognitive and Physical Training in Patients With Mild Cognitive Impairment overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12-31 date: 2024-12-31 date: 2024-04-10 date: 2024-04-10 name: MinYoung Kim, MD, PhD class: OTHER briefSummary: This is to find out the effectiveness of cognitive and physical function training for patients with mild cognitive impairment.
|
It is for the prevention and treatment of dementia in the future. randomized, Pilot Study. conditions: Patients With Mild Cognitive Impairment (MCI) studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Using tablets and workbooks cognitive function. name: self-programming of physical function training. measure: Montreal Cognitive Assessment (MoCA) measure: Korean-Mini Mental Status Examination (K-MMSE) measure: Clinical Dementia Rating (CDR) measure: Clinical Global Impressions of Change (CGIC) measure: Instrumental Activities of Daily Living (I-ADL) measure: Berg Balance Scale (BBS) measure: Geriatric Quality of Life-Dementia (GQOL-D) measure: Geriatric Depression Scale (GDSd) measure: Global Deterioration Scale (GDS) measure: Electroencephalography sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06355960 id: 2024-853 briefTitle: Effect of Dexmedetomidine on Oxygenation and Lung Mechanics overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2025-05-01 date: 2024-04-10 date: 2024-04-10 name: Cairo University class: OTHER briefSummary: Dexmedetomidine is a selective α -2 agonist widely used in anesthesia for its sympatholytic, sedative and analgesic effects . Favorable respiratory effects in animals , and in selected human patient groups have been reported when using this agent .we investigated the effects of different doses of dexmedetomidine infusion on oxygenation conditions: Drug Use conditions: Dexmedetomidine studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 176 type: ESTIMATED name: GROUP Dexmedetomidine name: GROUP B name: GROUP C measure: Oxygenation by the end study measure: Intraoperative dynamic lung compliance measure: Intraoperative static lung compliance measure: Physiological dead space sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cairo university city: Cairo zip: 11562 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
|
<|newrecord|> nctId: NCT06355947 id: 103-7445B briefTitle: Cycling and Treadmill With Dual Task for Parkinson's Disease Improvement overallStatus: COMPLETED date: 2015-12-07 date: 2017-09-11 date: 2018-07-31 date: 2024-04-10 date: 2024-04-10 name: Chang Gung University class: OTHER briefSummary: Motor impairment in lower extremities is common in individuals with Parkinson disease (PD). Development sensitive test for early motor deviations is important. Conventional walking test cannot induce the PD related motor impairments, such as freezing of gait. Therefore, finding a safe substitute test to induce PD related motor impairments is important.
|
Studies showed that working memory related dual task walking was a sensitive test for PD. However, the optimal cognitive test needs to be clarified. Studies also showed that the neuromuscular control mechanism of leg movements during cycling were similar to those during walking. Therefore, dual task cycling test is potential to be a safe and sensitive testing model.
|
Studies showed that exercise could improve cognitive function and induce brain plasticity. Dual task exercise training was shown to be more effective than single task exercise training for older people to prevent fall. Whether the added cognitive task could improve to detriment brain plasticity in PD should be investigated. Transcranial magnetic stimulation can evaluate the motor cortex plasticity on-invasively and can evaluate the exercise induced brain plasticity.
|
The purpose of this three-year project is to develop PD-sensitive. The purposes of the first year are to translate the dual task walking test to dual task cycling test, and to establish the reliability of the dual task cycling test.
|
The purposes of the second year are to compare the motor cortex plasticity induced by single task cycling versus dual task cycling and to compare the difference response between PD and healthy control people.
|
The purpose of the third year is to evaluate the effect of 8 week long term cycling training or treadmill training of individuals with PD on motor cortex plasticity, dual task performance, and ambulation ability. conditions: Parkinson Disease(PD) studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 50 type: ACTUAL name: Cognitive cycling training name: Cognitive treadmill training measure: Walking Speed measure: Step Length measure: Step Time measure: Power Spectral Density (PSD) measure: Task Accuracy measure: Reaction Time measure: Balance Performance measure: Double Support Time measure: Single Support Time measure: Swing Time measure: Stance Time measure: Cadence measure: Heart rate sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chang Gung University city: Taoyuan zip: 333 country: Taiwan lat: 24.95233 lon: 121.20193 hasResults: False
|
<|newrecord|> nctId: NCT06355934 id: D8450R00004 briefTitle: OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis acronym: OverTTuRe overallStatus: RECRUITING date: 2023-08-21 date: 2026-09-30 date: 2026-09-30 date: 2024-04-10 date: 2024-04-29 name: AstraZeneca class: INDUSTRY briefSummary: The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented. conditions: ATTR Amyloidosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 55000 type: ESTIMATED name: no intervention measure: Health Care Resource Utilization (HCRU) - Outpatient visits measure: Health Care Resource Utilization (HCRU) - Outpatient visits by specialty measure: Health Care Resource Utilization (HCRU) - Emergency department visits measure: Health Care Resource Utilization (HCRU) - Hospitalizations, length of stay measure: Health Care Resource Utilization (HCRU) - Hospitalizations measure: Health Care Resource Utilization (HCRU) - Health care cost measure: Cardiac transplant measure: All cause mortality measure: Liver transplant measure: Heart Failure Hospitalization measure: New ATTR amyloidosis clinical manifestation measure: Hospitalization (any cause) measure: Neuropathy Impairment Score (NIS) measure: Neuropathy Impairment Score Lower Limbs (NIS-LL) measure: Neuropathy Impairment Score +7 (NIS+7) measure: Neuropathy Impairment Score modified +7 (mNIS+7) measure: Neuropathy symptoms and change (NCS) score measure: PND (Polyneuropathy Disability) measure: Other relevant clinical measurement of ATTR amyloidosis functional status measure: Norfolk Quality of Life - Diabetic Neuropathy (Norfolk QoL-DN) Score measure: Health Care Resource Utilization (HCRU) - Outpatient visits measure: Health Care Resource Utilization (HCRU) - Outpatient visits by specialty measure: Health Care Resource Utilization (HCRU) - Emergency department visits measure: Health Care Resource Utilization (HCRU) - Hospitalizations, length of stay measure: Health Care Resource Utilization (HCRU) - Hospitalizations measure: Health Care Resource Utilization (HCRU) - Health care cost sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Research Site status: COMPLETED city: Eden Prairie state: Minnesota zip: 55344 country: United States lat: 44.85469 lon: -93.47079 facility: Research Site status: RECRUITING city: Horsens country: Denmark lat: 55.86066 lon: 9.85034 facility: Research Site status: COMPLETED city: Tokyo country: Japan lat: 35.6895 lon: 139.69171 facility: Research Site status: RECRUITING city: London country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
|
<|newrecord|> nctId: NCT06355921 id: RFAdesmoid briefTitle: A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors acronym: RFAdesmoid overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-02-01 date: 2028-05-01 date: 2024-04-10 date: 2024-04-10 name: Blokhin's Russian Cancer Research Center class: OTHER briefSummary: This is a prospective study on the safety and effectiveness of radiofrequency ablation in patients with desmoid tumors.
|
In the study group, all patients after radiofrequency ablation of the tumor after 1 month will be evaluated using MRI and CT studies and, if solid components of the tumor are detected, repeated surgical treatment is performed followed by active monitoring after 1 month.
|
In the absence of a solid component, the effect is estimated by the volume of the necrotic process and monitored in dynamics every 3 months. conditions: Desmoid Tumor conditions: Desmoid Fibromatosis conditions: Desmoid studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 27 type: ESTIMATED name: radiofrequency ablation measure: Comparison of safety assessment. measure: Overall Response Rate measure: Duration of responce measure: Comparison of tumor necrosis based on MRI/CT sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO) city: Moscow state: MO zip: 115522 country: Russian Federation name: Artem Galustov role: CONTACT phone: 9169117818 email: [email protected] name: Aslan Valiev, PhD role: PRINCIPAL_INVESTIGATOR name: Denis Sofronov, PhD role: SUB_INVESTIGATOR lat: 55.75222 lon: 37.61556 hasResults: False
|
<|newrecord|> nctId: NCT06355908 id: TT002 briefTitle: IL13Rα2 CAR-T for Patients With r/r Glioma acronym: ENHANCING overallStatus: RECRUITING date: 2024-03-21 date: 2026-05-01 date: 2027-05-01 date: 2024-04-10 date: 2024-04-10 name: Yang Zhang class: OTHER name: TCRCure Biopharma Ltd. briefSummary: This is a dose exploration clinical trial to assess the safety and feasibility of the IL13Ra2-targeted CAR-T in glioma. conditions: Glioma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: IL13Rα2 CAR-T measure: Safety of IL13Rα2 CAR-T measure: Overall Response Rate (ORR) measure: Duration of Response (DOR) measure: Progression Free Survival (PFS) measure: Overall Survival (OS) measure: Overall Survival (OS) at 6 months (OS6) measure: Overall Survival (OS) at 12 months (OS12) measure: The levels of IL13Rα2 CAR-T cell and IL13Rα2 CAR in the CSF and peripheral blood measure: The levels of cytokines in the CSF and peripheral blood measure: The Exploratory Indicators sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Tiantan Hospital status: RECRUITING city: Beijing country: China name: Yang Zhang, MD, phD role: CONTACT phone: +861059976516 email: [email protected] lat: 39.9075 lon: 116.39723 hasResults: False
|
<|newrecord|> nctId: NCT06355895 id: HCC 23-104 briefTitle: Liver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-04-10 date: 2024-04-10 name: University of Pittsburgh class: OTHER name: American College of Radiation Oncology briefSummary: Standard planning constraints for liver SBRT incorporate strict dose-volume limits for normal liver parenchyma to minimize the risk of radiation-induced liver disease. The presence of diurnal and fasting/fed variations in liver volume therefore carry substantial potential for introducing errors into estimates of dose-volume distribution within normal liver tissue, as well as affecting day-to-day setup fidelity and organ alignment for treatment. This prospective study will examine how diurnal and fast-fed variations in liver volume affect treatment planning for abdominal SBRT. conditions: Upper Abdominal Malignancies studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 17 type: ESTIMATED name: Standardized high-carbohydrate meal measure: Diurnal Difference in Liver Volumes measure: Difference in total liver volume measure: Percentage diurnal difference in liver mean dose at V5 Gy measure: Percentage diurnal difference in liver mean dose at V15Gy measure: Difference in liver mean dose at V15 Gy measure: Difference in liver dose at V15 Gy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UPMC Hillman Cancer Center city: Pittsburgh state: Pennsylvania zip: 15232 country: United States name: Samantha Demko role: CONTACT name: Brieanna Marino role: CONTACT name: Susannah Ellsworth, MD role: PRINCIPAL_INVESTIGATOR lat: 40.44062 lon: -79.99589 hasResults: False
|
<|newrecord|> nctId: NCT06355882 id: LCOSDental briefTitle: Patients With Low Cardiac Output Syndrome Undergoing Local Dental Anesthesia overallStatus: RECRUITING date: 2023-08-08 date: 2024-12-01 date: 2024-12-01 date: 2024-04-10 date: 2024-04-22 name: University of Sao Paulo General Hospital class: OTHER name: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. briefSummary: Patients with low cardiac output syndrome requiring surgical and periodontal dental treatment will be selected to undergo the dental procedure using local dental anesthetic: 2% lidocaine with epinephrine and 2% lidocaine without vasoconstrictor. Cardiovascular events and the safety of using two cartridges (3.6 mL) will be evaluated. They will be evaluated by Holter monitoring in the period of 1 hour before, during and 1 hour after the procedure and blood pressure correction will be performed conditions: Low Cardiac Output Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 29 type: ESTIMATED name: Anesthetic infiltration measure: Amount ventricular and supraventricular arrhythmia sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Instituto do Coração HCFMUSP status: RECRUITING city: São Paulo zip: 05403000 country: Brazil name: Itamara LI Neves, PhD role: CONTACT phone: 1126615229 email: [email protected] name: Mariana DC Dias role: CONTACT phone: 19996614440 email: [email protected] name: Itamara LI Neves, PhD role: PRINCIPAL_INVESTIGATOR lat: -23.5475 lon: -46.63611 hasResults: False
|
<|newrecord|> nctId: NCT06355869 id: s65337 briefTitle: Repeatability of Gait Deviations in Children With Cerebral Palsy overallStatus: COMPLETED date: 2021-08-17 date: 2023-05-31 date: 2023-05-31 date: 2024-04-10 date: 2024-04-15 name: Universitaire Ziekenhuizen KU Leuven class: OTHER briefSummary: Three-dimensional gait analysis (3DGA) is the 'gold standard' for measurement and description of gait. Gait variability can arise from intrinsic and extrinsic factors and may vary between walking conditions. This study aimed to define the inter-trial (intrinsic) and inter-session (extrinsic) repeatability in gait analysis data of children with CP who were walking in four conditions, namely barefoot or with ankle-foot orthosis, and overground or treadmill. conditions: Spastic Cerebral Palsy studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 10 type: ACTUAL name: repeated 3D gait-analysis measure: The standard error of measurement (SEM) of the continuous kinematic gait waveforms measure: The intra-class correlation (ICC) of the gait indices measure: The standard error of measurement (SEM) of the continuous kinetic gait waveforms measure: The standard error of measurement (SEM) of the gait indices sex: ALL minimumAge: 6 Years maximumAge: 17 Years stdAges: CHILD facility: UZ Leuven city: Leuven state: Vlaams-Brabant zip: 3000 country: Belgium lat: 50.87959 lon: 4.70093 hasResults: False
|
<|newrecord|> nctId: NCT06355856 id: ACH-PNT-04(01/22) briefTitle: Efficacy/ Safety of DNN.22.17.036 in Male Patients With Pattern Hair Loss acronym: CAPELLI overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-05 date: 2025-05 date: 2024-04-10 date: 2024-04-10 name: Ache Laboratorios Farmaceuticos S.A. class: INDUSTRY briefSummary: Evaluation of the efficacy and safety of DNN.22.17.036 versus 10573048700 in the treatment of male pattern hair loss. conditions: Alopecia studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 196 type: ESTIMATED name: DNN.22.17.036 name: 10573048700 measure: Percentage variation of hairs in the hair loss phase sex: MALE minimumAge: 25 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06355843 id: SXY briefTitle: Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer. overallStatus: SUSPENDED date: 2022-04-28 date: 2023-09-30 date: 2027-03-31 date: 2024-04-09 date: 2024-04-09 name: The First Affiliated Hospital of Anhui Medical University class: OTHER name: National Natural Science Foundation of China briefSummary: The goal of this study type: observational study (prospective study) is to study prostate cancer occurrence and recurrence, to specifically identify and localize tumor foci at the molecular level at an early stage, to evaluate the prognosis of patients, and to accurately stage not only intermediate- and high-risk prostate cancer patients with a primary diagnosis, but also detect recurrent foci in patients with biochemical recurrence, to restage those who have developed metastases, to assess tumor load, and to ultimately assist in determining the personalized treatment plans. The main question it aims to answer is whether 68Ga-PSMA PET/CT (PET/MR) examination is beneficial for assessing the
|
* Accurate staging of patients with intermediate- and high-risk prostate cancer at first diagnosis;
|
* Detecting recurrent lesions in patients with recurrent tumors for re-staging;
|
* Assessment of tumor load;
|
* Assessment of patient prognosis. Participants will sign an informed consent form, undergo 68Ga-PSMA PET/CT (PET/MR) before surgery or biopsy, and have regular follow-up after obtaining pathological results of surgical resection or puncture biopsy, 6 weeks after surgery or biopsy, and then every 3 months; the follow-up will include: blood PSA, whole-body bone imaging, etc. conditions: Prostate Cancer conditions: Pet-ct studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 50 type: ESTIMATED name: 68Ga-PSMA measure: Measuring the value of 68Ga-PSMA PET/MRI in the diagnosis and staging of primary prostate cancer and comparing it with mp-MRI and PET/CT measure: Exploring whether 68Ga-PSMA PET/MRI can be used as a method for diagnostic efficacy sex: MALE minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: First affiliated hospital of anhui university city: Hefei state: Anhui zip: 230032 country: China lat: 31.86389 lon: 117.28083 hasResults: False
|
<|newrecord|> nctId: NCT06355830 id: RETimaging4iAMD briefTitle: Intermediate Age-related Macular Degeneration - Multimodal Analysis and Longitudinal Study acronym: Imaging4iAMD overallStatus: RECRUITING date: 2019-01-02 date: 2025-06 date: 2026-06 date: 2024-04-09 date: 2024-04-09 name: Universidade Nova de Lisboa class: OTHER name: iNOVA4Health, NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, UNL name: Centro Hospitalar de Lisboa Central EPE, Lisboa, Portugal name: Centro Hospitalar Universitário de São João, Porto, Portugal briefSummary: Study: observational prospective clinical study. Study population: Subjects over 55 years old with drusen secondary to intermediate AMD.
|
Recruitment: at the Medical Retinal Consultation from the Ophthalmology Department of CHULC.
|
Primary outcome: Identifying imaging predictors of iAMD progression. conditions: Age-Related Macular Degeneration studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: Orthoptic assessment (Outcome measure) measure: Change in incomplete retinal pigment epithelial and outer retinal atrophy (iRORA) from baseline measure: Change in Drusen morphology from baseline measure: Change in Subfoveal drusen area from baseline measure: Change in other drusen area from baseline measure: Change in Drusen reflectivity from baseline measure: Change in other Drusen homogeneity from baseline measure: Change in ellipsoid zone disruption from baseline measure: Change in Drusen homogeneity from baseline measure: Change in hyperreflective foci from baseline measure: Change in hyperreflective foci location (within 500-μm disc area) from baseline measure: Change in hyperreflective foci association to drusen from baseline measure: Progression to Moderate Vision Loss measure: Geographic Atrophy (GA) Growth Rate measure: Progression to Advanced AMD according to international classification/grading system sex: ALL minimumAge: 55 Years maximumAge: 95 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ophthalmology Service, Centro Hospitalar de Lisboa Central EPE status: RECRUITING city: Lisbon zip: 1150-199 country: Portugal name: Rita Flores, MD role: CONTACT phone: 00351218841000 phoneExt: 21355 email: [email protected] lat: 38.71667 lon: -9.13333 hasResults: False
|
<|newrecord|> nctId: NCT06355817 id: HS25941 briefTitle: Distraction Techniques in Periocular Anesthesia: Tapping vs Vibration overallStatus: COMPLETED date: 2023-09-21 date: 2024-03-19 date: 2024-03-19 date: 2024-04-09 date: 2024-04-22 name: University of Manitoba class: OTHER name: Winnipeg Regional Health Authority briefSummary: To compare the efficacy of topical tapping vs vibration in lowering pain scores for periocular anesthesia injections. conditions: Anesthetics, Local conditions: Blepharoplasty conditions: Age-Related Ptosis conditions: Adult conditions: Humans conditions: Lidocaine conditions: Ophthalmologic Surgical Procedure conditions: Vibration conditions: Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Each patient will receive both interventions and serve as their own comparator. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: The participant and surgeon was not made aware of which intervention the participant would receive first until the time of the procedure. Randomization was made at the time of the procedure. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 80 type: ACTUAL name: Vibration name: Tapping measure: Pain Reduction in Tapping vs Vibration distraction techniques in peri-ocular local anesthesia measure: Difference in Pain Reduction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Misericordia Health Centre city: Winnipeg state: Manitoba zip: R3C 1A2 country: Canada lat: 49.8844 lon: -97.14704 hasResults: False
|
<|newrecord|> nctId: NCT06355804 id: STUDY2023-1565 briefTitle: Lifestyle Physical Activity Intervention for Persons Newly Diagnosed With Multiple Sclerosis overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2025-04-22 date: 2025-04-22 date: 2024-04-09 date: 2024-04-09 name: University of Illinois at Chicago class: OTHER briefSummary: The overall objective of the current study is to determine the efficacy of a 16-week remotely delivered lifestyle behavioral intervention compared with a control condition (i.e., waitlist control) in persons newly diagnosed with MS (disease duration ≤ 2 years).
|
Specific Aim 1: To evaluate the changes in self-report and device-measured physical activity after the 16-week remotely delivered physical activity behavior change intervention compared with a control condition (i.e., waitlist control) in persons who have diagnosed with MS within the past two years. The investigators hypothesize that the 16-week behavior change intervention will yield greater improvements in physical activity levels than the control condition immediately after the intervention.
|
Specific Aim 2: To investigate the efficacy of the 16-week, remotely delivered physical activity behavior change intervention compared with the control condition for improvements in fatigue, depression, anxiety, and QoL in persons newly diagnosed with MS. The investigators hypothesize that there will be beneficial effects on the symptoms and QoL outcomes immediately after the physical activity intervention compared with minimal changes in the control condition. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 50 type: ESTIMATED name: Physical activity condition name: Waitlist condition measure: Physical Activity Behavior measure: Physical Activity Behavior measure: Physical Activity Level (Light physical activity) measure: Physical Activity Level (Moderate-to-vigorous physical activity) measure: Physical Activity Level (Daily step count) measure: Health-related quality of Life measure: Health-related Quality of Life measure: Fatigue Severity measure: Depressive Symptoms measure: Anxiety sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06355791 id: PDPROJ-4-TP-001-23 briefTitle: The Stability Study acronym: STABILITY overallStatus: ENROLLING_BY_INVITATION date: 2024-04-15 date: 2025-04-30 date: 2025-09-30 date: 2024-04-09 date: 2024-04-09 name: Spinal Simplicity LLC class: INDUSTRY briefSummary: The studied indication is degenerative conditions of the lumbar spine resulting in back pain with lower extremity symptoms and neurogenic claudication.
|
The purpose of this study is to evaluate the effectiveness and safety of instrumented posterior arthrodesis using the Spinal Simplicity Minuteman G5 MIS Fusion Plate and bone graft material in patients with degenerative conditions of the lumbar spine resulting in chronic low back pain with lower extremity symptoms and concurrent neurogenic claudication. conditions: Lumbar Spinal Stenosis conditions: Spondylolisthesis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 150 type: ESTIMATED name: Minuteman G5 measure: NRS Back and Leg measure: ODI measure: PROMIS 29 2.0 measure: 12 Month Fusion Assessment sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kansas University Medical Center city: Kansas City state: Kansas zip: 66160 country: United States lat: 39.11417 lon: -94.62746 hasResults: False
|
<|newrecord|> nctId: NCT06355778 id: HUM00234185 id: 1R01DA056415 type: NIH link: https://reporter.nih.gov/quickSearch/1R01DA056415 briefTitle: Adversity, Brain and Opioid Use Study overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-04 date: 2028-04 date: 2024-04-09 date: 2024-04-09 name: University of Michigan class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: The way people process and remember information may be related to adverse childhood experiences and Opioid Use Disorder symptoms. The purpose of this project is to examine brain function and performance during learning and memory tasks in adults. The study will compare measures of learning and memory across three groups of participants: those with an Opioid Use Disorder (OUD) that take buprenorphine for opioid replacement therapy, adults without an Opioid Use Disorder taking buprenorphine, and healthy adults that do not have an Opioid Use Disorder and are not taking buprenorphine. conditions: Opioid Use Disorder conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 315 type: ESTIMATED name: Magnetic Resonance Imaging (MRI) name: Computer Tasks measure: Differences in Blood Oxygen Level Dependent (BOLD) signal in the hippocampus measure: Differences in Hippocampal (Hpc) volume measure: Differences in hippocampal circuit connectivity measure: Differences in performance measure: Differences in performance measure: Differences in threat reactivity measured via skin conductance response (SCR) measure: Differences in threat reactivity measured via skin conductance response (SCR) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: University of Michigan city: Ann Arbor state: Michigan zip: 48109 country: United States name: Mariya Churina role: CONTACT email: [email protected] name: Elizabeth Duval, PhD role: PRINCIPAL_INVESTIGATOR lat: 42.27756 lon: -83.74088 hasResults: False
|
<|newrecord|> nctId: NCT06355765 id: CITIZ_001 briefTitle: Citicoline & Antioxidants in Glaucoma overallStatus: COMPLETED date: 2022-01-10 date: 2022-12-10 date: 2022-12-10 date: 2024-04-09 date: 2024-04-17 name: University of Naples class: OTHER briefSummary: To evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) using optical coherence tomography (OCT), OCT angiography (OCTA) and microperimetry parameters. conditions: Glaucoma, Open-Angle studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 60 type: ACTUAL name: Citicoline blackcurrant supplement measure: Evaluation of Ganglionar cells complex (GCC) measure: Evaluation of Retinal nerve fiber layer (RNFL) sex: ALL minimumAge: 30 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Naples Federico II city: NAples zip: 80131 country: Italy lat: 40.85216 lon: 14.26811 hasResults: False
|
<|newrecord|> nctId: NCT06355752 id: 0018-N-23 briefTitle: Biomarkers of Pain and Stress Perception and Dry Needling Technique Application overallStatus: RECRUITING date: 2024-04-12 date: 2024-07-15 date: 2024-07-15 date: 2024-04-09 date: 2024-04-16 name: University of Alcala class: OTHER briefSummary: The use of the dry needling technique has become widespread in recent years for the treatment of musculoskeletal pain. Although dry needling has been shown to be effective in the treatment of shoulder pain, elbow pain, headache, etc., we do not yet have a clear understanding of the mechanisms of action that justify its beneficial effects.
|
In this study, we propose to analyse the biochemical markers of pain generated by the application of a dry needling technique on the lumbar musculature in patients with mechanical lumbar pain of non-specific origin.
|
The aim of this study will be to evaluate the effects of dry needling technique on the plasmatic concentration of biochemical markers.Furthermore, the test subjects will be randomly distributed into two groups.
|
An experimental group where the subjects will receive a real dry needling technique.
|
Another group will be treated with a sham technique. conditions: Low Back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 36 type: ESTIMATED name: Dry needling of lumbar iliocostalis muscle name: Sham dry needling lumbar iliocostalis muscle measure: Extracting Blood Samples and Obtaining Serum/Plasma sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centro Investigación Fisioterapia y Dolor status: RECRUITING city: Alcalá De Henares state: Madrid zip: 28805 country: Spain name: Patricia Martinez-Merinero, PhD role: CONTACT phone: 683378391 email: [email protected] name: Laura Cabellos role: CONTACT phone: 683378391 email: [email protected] lat: 40.48205 lon: -3.35996 hasResults: False
|
<|newrecord|> nctId: NCT06355739 id: BIC-19GG, BIC-2019,BIC-2219 briefTitle: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+ overallStatus: RECRUITING date: 2024-02-01 date: 2026-12-01 date: 2027-01-15 date: 2024-04-09 date: 2024-04-09 name: Zhu Xiaofan class: OTHER briefSummary: To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children conditions: B Lymphocytic Leukemia conditions: B Lymphoblastic Lymphoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: CAR T cell injection measure: Overall survival and event-free survival measure: Overall remission rate measure: Adverse events sex: ALL minimumAge: 3 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences status: RECRUITING city: Tianjin state: Tianjin zip: 300020 country: China name: Xiaofan Zhu, MD role: CONTACT phone: 86-21-23909001 email: [email protected] name: Jingliao Zhang, MD role: SUB_INVESTIGATOR lat: 39.14222 lon: 117.17667 facility: InstituteHBDH status: NOT_YET_RECRUITING city: Tianjin state: Tianjin zip: 300020 country: China name: Zhu Xiaofan role: CONTACT phone: 86-21-23909001 email: [email protected] name: Guo Ye role: PRINCIPAL_INVESTIGATOR name: Yang Wenyu role: PRINCIPAL_INVESTIGATOR name: Chen Xiaojuan role: PRINCIPAL_INVESTIGATOR name: Chen Yumei role: PRINCIPAL_INVESTIGATOR name: Ruan Min role: PRINCIPAL_INVESTIGATOR lat: 39.14222 lon: 117.17667 hasResults: False
|
<|newrecord|> nctId: NCT06355726 id: ILBS-Alcoholic Hepatitis-03 briefTitle: Efficacy of Plasma Exchange Therapy vs Standard Medical Therapy in Severe Alcoholic Hepatitis With High Discriminant Function overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-02-28 date: 2025-02-28 date: 2024-04-09 date: 2024-04-09 name: Institute of Liver and Biliary Sciences, India class: OTHER briefSummary: Alcoholic hepatitis, the most florid form of alcoholic liver disease, has a very high short-term mortality of up to 50% and no specific therapies are available other than steroids. Steroids also only show a limited utility in improving the short-term survival and boast no evidence of any long-term benefits. Additionally, only a small proportion of patients with alcoholic hepatitis are eligible to receive steroids. Thus, a large number of patients are either not eligible or do not respond to steroids and this group outnumbers those who do respond to steroids, leaving us without any specific therapeutic options for a majority of these individuals.\[1\] Even liver transplantation is not feasible in most cases due to the presence of sepsis or recent alcohol consumption and many ethical and logistic issues are involved despite the documented safety and survival benefits of early liver transplantation in patients with severe alcoholic hepatitis (SAH) not responding to medical management.\[2,8\] Therefore, newer, more effective, and nontransplant therapeutic options for managing severe alcoholic hepatitis are needed. TPE is expected to be an effective and well-tolerated bridge therapy in patients with severe alcoholic hepatitis of moderate severity not improving on SMT and without immediate prospects for liver transplantation. conditions: Alcoholic Hepatitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Plasma Exchange name: Standard Medical Treatment measure: Liver transplant free survival at 28 days, 90 days and 180 days. measure: Change in total bilirubin and INR as measured by Discriminant Functions measure: Number of patients with change in Model for End Stage Liver Disease (MELD) measure: Number of patients with change in CTP measure: Number of patients with change in LSM,SSM measure: Mortality in both groups measure: clinical improvement in the form of jaundice as measured by total bilirubin measure: clinical improvement in the form of hepatic encephalopathy as measured by west haven criteria measure: clinical improvement in the form of ascites as measured by ICA criteria. measure: Frequency of decompensation events on follow up period measure: Adverse events during plasma exchange sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Institute of Liver & Biliary Sciences (ILBS) city: New Delhi state: Delhi zip: 110070 country: India lat: 28.63576 lon: 77.22445 hasResults: False
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.